Ronald van Vollenhoven

Publikationer
CV
Populärvetenskap och samverkan

Artiklar

Article: ARTHRITIS CARE AND RESEARCH. 2020;72(12):1800-1808
Economic Evaluation of Damage Accrual in an International Systemic Lupus Erythematosus Inception Cohort Using a Multistate Model Approach.
Barber MRW; Hanly JG; Su L; Urowitz MB; St Pierre Y; Romero-Diaz J; Gordon C; Bae S-C; Bernatsky S; Wallace DJ; Merrill JT; Isenberg DA; Rahman A; Ginzler EM; Petri M; Bruce IN; Dooley MA; Fortin PR; Gladman DD; Sanchez-Guerrero J; Steinsson K; Ramsey-Goldman R; Khamashta MA; Aranow C; Mackay M; Alarcón GS; Manzi S; Nived O; Jönsen A; Zoma AA; van Vollenhoven RF; Ramos-Casals M; Ruiz-Irastorza G; Lim SS; Kalunian KC; Inanc M; Kamen DL; Peschken CA; Jacobsen S; Askanase A; Farewell V; Stoll T; Buyon J; Clarke AE
Article: ARTHRITIS & RHEUMATOLOGY. 2020;72(4):658-666
Prediction of Damage Accrual in Systemic Lupus Erythematosus Using the Systemic Lupus International Collaborating Clinics Frailty Index
Legge A; Kirkland S; Rockwood K; Andreou P; Bae S-C; Gordon C; Romero-Diaz J; Sanchez-Guerrero J; Wallace DJ; Bernatsky S; Clarke AE; Merrill JT; Ginzler EM; Fortin PR; Gladman DD; Urowitz MB; Bruce IN; Isenberg DA; Rahman A; Alarcon GS; Petri M; Khamashta MA; Dooley MA; Ramsey-Goldman R; Manzi S; Zoma AA; Aranow C; Mackay M; Ruiz-Irastorza G; Lim SS; Inanc M; van Vollenhoven RF; Jonsen A; Nived O; Ramos-Casals M; Kamen DL; Kalunian KC; Jacobsen S; Peschken CA; Askanase A; Hanly JG
Article: ANNALS OF THE RHEUMATIC DISEASES. 2020;79(3):356-362
Neuropsychiatric events in systemic lupus erythematosus: a longitudinal analysis of outcomes in an international inception cohort using a multistate model approach.
Hanly JG; Urowitz MB; Gordon C; Bae S-C; Romero-Diaz J; Sanchez-Guerrero J; Bernatsky S; Clarke AE; Wallace DJ; Isenberg DA; Rahman A; Merrill JT; Fortin PR; Gladman DD; Bruce IN; Petri M; Ginzler EM; Dooley MA; Ramsey-Goldman R; Manzi S; Jönsen A; Alarcón GS; van Vollenhoven RF; Aranow C; Mackay M; Ruiz-Irastorza G; Lim S; Inanc M; Kalunian KC; Jacobsen S; Peschken CA; Kamen DL; Askanase A; Farewell V
Article: JOURNAL OF AUTOIMMUNITY. 2020;106:102340
Soluble urokinase plasminogen activator receptor (suPAR) levels predict damage accrual in patients with recent-onset systemic lupus erythematosus
Enocsson H; Wirestam L; Dahle C; Padyukov L; Jonsen A; Urowitz MB; Gladman DD; Romero-Diaz J; Bae S-C; Fortin PR; Sanchez-Guerrero J; Clarke AE; Bernatsky S; Gordon C; Hanly JG; Wallace DJ; Isenberg DA; Rahman A; Merrill JT; Ginzler E; Alarcon GS; Chatham WW; Petri M; Khamashta M; Aranow C; Mackay M; Dooley MA; Manzi S; Ramsey-Goldman R; Nived O; Steinsson K; Zoma AA; Ruiz-Irastorza G; Lim SS; Kalunian KC; Inanc M; van Vollenhoven RF; Ramos-Casals M; Kamen DL; Jacobsen S; Peschken CA; Askanase A; Stoll T; Bruce IN; Wettero J; Sjowall C
Article: ARTHRITIS & RHEUMATOLOGY. 2020;72(1):67-77
Peripheral Nervous System Disease in Systemic Lupus Erythematosus: Results From an International Inception Cohort Study
Hanly JG; Li Q; Su L; Urowitz MB; Gordon C; Bae S-C; Romero-Diaz J; Sanchez-Guerrero J; Bernatsky S; Clarke AE; Wallace DJ; Isenberg DA; Rahman A; Merrill JT; Fortin PR; Gladman DD; Bruce IN; Petri M; Ginzler EM; Dooley MA; Steinsson K; Ramsey-Goldman R; Zoma AA; Manzi S; Nived O; Jonsen A; Khamashta MA; Alarcon GS; Svenungsson E; van Vollenhoven RF; Aranow C; Mackay M; Ruiz-Irastorza G; Ramos-Casals M; Lim SS; Inanc M; Kalunian KC; Jacobsen S; Peschken CA; Kamen DL; Askanase A; Theriault C; Farewell V
Article: JOURNAL OF RHEUMATOLOGY. 2020;47(1):72-81
Construction of a Frailty Index as a Novel Health Measure in Systemic Lupus Erythematosus
Legge A; Kirkland S; Rockwood K; Andreou P; Bae S-C; Gordon C; Romero-Diaz J; Sanchez-Guerrero J; Wallace DJ; Bernatsky S; Clarke AE; Merrill JT; Ginzler EM; Fortin P; Gladman DD; Urowitz MB; Bruce IN; Isenberg DA; Rahman A; Alarcon GS; Petri M; Khamashta MA; Dooley MA; Ramsey-Goldman R; Manzi S; Zoma AA; Aranow C; Mackay M; Ruiz-Irastorza G; Lim SS; Inanc M; van Vollenhoven RF; Jonsen A; Nived O; Ramos-Casals M; Kamen DL; Kalunian KC; Jacobsen S; Peschken CA; Askanase A; Hanly JG
Article: SCANDINAVIAN JOURNAL OF RHEUMATOLOGY. 2019;48(5):362-366
Association of female sex and positive rheumatoid factor with low serum infliximab and anti-drug antibodies, related to treatment failure in early rheumatoid arthritis: results from the SWEFOT trial population
Hambardzumyan K; Hermanrud C; Marits P; Vivar N; Ernestam S; Wallman JK; van Vollenhoven RF; Fogdell-Hahn A; Saevarsdottir S
Article: ARTHRITIS & RHEUMATOLOGY. 2019;71(8):1297-1307
Evaluating the Properties of a Frailty Index and Its Association With Mortality Risk Among Patients With Systemic Lupus Erythematosus
Legge A; Kirkland S; Rockwood K; Andreou P; Bae S-C; Gordon C; Romero-Diaz J; Sanchez-Guerrero J; Wallace DJ; Bernatsky S; Clarke AE; Merrill JT; Ginzler EM; Fortin P; Gladman DD; Urowitz MB; Bruce IN; Isenberg DA; Rahman A; Alarcon GS; Petri M; Khamashta MA; Dooley MA; Ramsey-Goldman R; Manzi S; Steinsson K; Zoma AA; Aranow C; Mackay M; Ruiz-Irastorza G; Lim SS; Nanc MI; van Vollenhoven RF; Jonsen A; Nived O; Ramos-Casals M; Kamen DL; Kalunian KC; Jacobsen S; Peschken CA; Askan N; Hanly JG
Article: CLINICAL PHARMACOLOGY AND THERAPEUTICS. 2019;106(2):374-382
A Prospective International Study on Adherence to Treatment in 305 Patients With Flaring SLE: Assessment by Drug Levels and Self-Administered Questionnaires
Costedoat-Chalumeau N; Houssiau F; Izmirly P; Le Guern V; Navarra S; Jolly M; Ruiz-Irastorza G; Baron G; Hachulla E; Agmon-Levin N; Shoenfeld Y; Dall'Ara F; Buyon J; Deligny C; Cervera R; Lazaro E; Bezanahary H; Leroux G; Morel N; Viallard J-F; Pineau C; Galicier L; Van Vollenhoven R; Tincani A; Hanh N; Gondran G; Zahr N; Pouchot J; Piette J-C; Petri M; Isenberg D
Article: RHEUMATOLOGY. 2019;58(7):1259-1267
Use of combined hormonal contraceptives among women with systemic lupus erythematosus with and without medical contraindications to oestrogen
Mendel A; Bernatsky S; Pineau CA; St-Pierre Y; Hanly JG; Urowitz MB; Clarke AE; Romero-Diaz J; Gordon C; Bae S-C; Wallace DJ; Merrill JT; Buyon J; Isenberg DA; Rahman A; Ginzler EM; Petri M; Dooley MA; Fortin P; Gladman DD; Steinsson K; Ramsey-Goldman R; Khamashta MA; Aranow C; Mackay M; Alarcon G; Manzi S; Nived O; Jonsen A; Zoma AA; van Vollenhoven RF; Ramos-Casals M; Ruiz-Irastorza G; Lim S; Kalunian KC; Inanc M; Kamen DL; Peschken CA; Jacobsen S; Askanase A; Sanchez-Guerrero J; Bruce IN; Costedoat-Chalumeau N; Vinet E
Article: ARTHRITIS CARE AND RESEARCH. 2019;71(7):893-902
Antinuclear Antibody-Negative Systemic Lupus Erythematosus in an International Inception Cohort.
Choi MY; Clarke AE; St Pierre Y; Hanly JG; Urowitz MB; Romero-Diaz J; Gordon C; Bae S-C; Bernatsky S; Wallace DJ; Merrill JT; Isenberg DA; Rahman A; Ginzler EM; Petri M; Bruce IN; Dooley MA; Fortin PR; Gladman DD; Sanchez-Guerrero J; Steinsson K; Ramsey-Goldman R; Khamashta MA; Aranow C; Alarcón GS; Manzi S; Nived O; Zoma AA; van Vollenhoven RF; Ramos-Casals M; Ruiz-Irastorza G; Lim SS; Kalunian KC; Inanc M; Kamen DL; Peschken CA; Jacobsen S; Askanase A; Stoll T; Buyon J; Mahler M; Fritzler MJ
Article: JOURNAL OF RHEUMATOLOGY. 2019;46(6):555-563
Serum Biomarkers for Prediction of Response to Methotrexate Monotherapy in Early Rheumatoid Arthritis: Results from the SWEFOT Trial
Hambardzumyan K; Bolce RJ; Wallman JK; van Vollenhoven RF; Saevarsdottir S
Article: JOURNAL OF RHEUMATOLOGY. 2019;46(5):492-500
Osteopontin and Disease Activity in Patients with Recent-onset Systemic Lupus Erythematosus: Results from the SLICC Inception Cohort
Wirestam L; Enocsson H; Skogh T; Padyukov L; Jonsen A; Urowitz MB; Gladman DD; Romero-Diaz J; Bae S-C; Fortin PR; Sanchez-Guerrero J; Clarke AE; Bernatsky S; Gordon C; Hanly JG; Wallace D; Isenberg DA; Rahman A; Merrill J; Ginzler E; Alarcon GS; Chatham WW; Petri M; Khamashta M; Aranow C; Mackay M; Dooley MA; Manzi S; Ramsey-Goldman R; Nived O; Steinsson K; Zoma A; Ruiz-Irastorza G; Lim S; Kalunian K; Inanc M; van Vollenhoven R; Ramos-Casals M; Kamen DL; Jacobsen S; Peschken C; Askanase A; Stoll T; Bruce IN; Wettero J; Sjowall C
Article: ARTHRITIS & RHEUMATOLOGY. 2019;71(2):281-289
Psychosis in Systemic Lupus Erythematosus: Results From an International Inception Cohort Study
Hanly JG; Li Q; Su L; Urowitz MB; Gordon C; Bae S-C; Romero-Diaz J; Sanchez-Guerrero J; Bernatsky S; Clarke AE; Wallace DJ; Isenberg DA; Rahman A; Merrill JT; Fortin PR; Gladman DD; Bruce IN; Petri M; Ginzler EM; Dooley MA; Steinsson K; Ramsey-Goldman R; Zoma AA; Manzi S; Nived O; Jonsen A; Khamashta MA; Alarcon GS; van Vollenhoven RF; Aranow C; Mackay M; Ruiz-Irastorza G; Ramos-Casals M; Lim SS; Inanc M; Kalunian KC; Jacobsen S; Peschken CA; Kamen DL; Askanase A; Theriault C; Farewell V
Article: EXPERT OPINION ON BIOLOGICAL THERAPY. 2019;19(2):157-168
Clinical SLEDAI-2K zero may be a pragmatic outcome measure in SLE studies
Parodis I; Emamikia S; Gomez A; Gunnarsson I; van Vollenhoven RF; Chatzidionysiou K
Article: SCANDINAVIAN JOURNAL OF RHEUMATOLOGY. 2019;48(1):17-23
Smoking and response to rituximab in rheumatoid arthritis: results from an international European collaboration
Chatzidionysiou K; Lukina G; Gabay C; Hetland ML; Hauge EM; Pavelka K; Nordstrom D; Canhao H; Tomsic M; Rotar Z; Lie E; Kvien TK; van Vollenhoven RF; Saevarsdottir S
Article: JOURNAL OF MANIPULATIVE AND PHYSIOLOGICAL THERAPEUTICS. 2019;42(1):34-46
Joint Mobilization of the Hands of Patients With Rheumatoid Arthritis: Results From an Assessor-Blinded, Randomized Crossover Trial
Levitsky A; Kisten Y; Lind S; Nordstrom P; Hultholm H; Lyander J; Hammelin V; Gentline C; Giannakou I; Faustini F; Skillgate E; van Vollenhoven R; Sundberg T
Article: ARTHRITIS CARE AND RESEARCH. 2018;70(10):1478-1487
Cerebrovascular Events in Systemic Lupus Erythematosus: Results From an International Inception Cohort Study
Hanly JG; Li Q; Su L; Urowitz MB; Gordon C; Bae S-C; Romero-Diaz J; Sanchez-Guerrero J; Bernatsky S; Clarke AE; Wallace DJ; Isenberg DA; Rahman A; Merrill JT; Fortin P; Gladman DD; Bruce IN; Petri M; Ginzler EM; Dooley MA; Steinsson K; Ramsey-Goldman R; Zoma AA; Manzi S; Nived O; Jonsen A; Khamashta MA; Alarcon GS; Chatham W; van Vollenhoven RF; Aranow C; Mackay M; Ruiz-Irastorza G; Ramos-Casals M; Lim SS; Inanc M; Kalunian KC; Jacobsen S; Peschken CA; Kamen DL; Askanase A; Theriault C; Farewell V
Article: ARTHRITIS CARE AND RESEARCH. 2018;70(9):1294-1302
Economic Evaluation of Lupus Nephritis in the Systemic Lupus International Collaborating Clinics Inception Cohort Using a Multistate Model Approach
Barber MRW; Hanly JG; Su L; Urowitz MB; St Pierre Y; Romero-Diaz J; Gordon C; Bae S-C; Bernatsky S; Wallace DJ; Isenberg DA; Rahman A; Ginzler EM; Petri M; Bruce IN; Fortin PR; Gladman DD; Sanchez-Guerrero J; Ramsey-Goldman R; Khamashta MA; Aranow C; Mackay M; Alarcon GS; Manzi S; Nived O; Jonsen A; Zoma AA; van Vollenhoven RF; Ramos-Casals M; Ruiz-Irastorza G; Lim SS; Kalunian KC; Inanc M; Kamen DL; Peschken CA; Jacobsen S; Askanase A; Theriault C; Farewell V; Clarke AE
Article: LUPUS. 2018;27(9):1470-1478
Rituximab-mediated late-onset neutropenia in systemic lupus erythematosus - distinct roles of BAFF and APRIL
Parodis I; Soder F; Faustini F; Kasza Z; Samuelsson I; Zickert A; Svenungsson E; van Vollenhoven RF; Malmstrom V; Wermeling F; Gunnarsson I
Article: PHARMACOGENOMICS JOURNAL. 2018;18(4):528-538
Genome-wide association study of response to methotrexate in early rheumatoid arthritis patients
Taylor JC; Bongartz T; Massey J; Mifsud B; Spiliopoulou A; Scott IC; Wang J; Morgan M; Plant D; Colombo M; Orchard P; Twigg S; McInnes IB; Porter D; Freeston JE; Nam JL; Cordell HJ; Isaacs JD; Strathdee JL; Arnett D; de Hair MJH; Tak PP; Aslibekyan S; van Vollenhoven RF; Padyukov L; Bridges SL; Pitzalis C; Cope AP; Verstappen SMM; Emery P; Barnes MR; Agakov F; McKeigue P; Mushiroda T; Kubo M; Weinshilboum R; Barton A; Morgan AW; Barrett JH
Article: INTERNATIONAL JOURNAL OF RHEUMATOLOGY. 2018;2018:9152480-7
Long-Term Dietary Changes after Diagnosis of Rheumatoid Arthritis in Swedish Women: Data from a Population-Based Cohort
Lourdudoss C; Arnaud L; Wolk A; van Vollenhoven RF; Di Giuseppe D
Article: CLINICAL PHARMACOLOGY AND THERAPEUTICS. 2018;103(6):1074-1082
A Prospective International Study on Adherence to Treatment in 305 Patients With Flaring SLE: Assessment by Drug Levels and Self-Administered Questionnaires
Costedoat-Chalumeau N; Houssiau F; Izmirly P; Le Guern V; Navarra S; Jolly M; Ruiz-Irastorza G; Baron G; Hachulla E; Agmon-Levin N; Shoenfeld Y; Dall'Ara F; Buyon J; Deligny C; Cervera R; Lazaro E; Bezanahary H; Leroux GE; Morel N; Viallard J-F; Pineau C; Galicier L; Van Vollenhoven R; Tincani A; Nguyen H; Gondran G; Zahr N; Pouchot J; Piette J-C; Petri M; Isenberg D
Article: RHEUMATOLOGY. 2018;57(4):677-687
Glucocorticoid use and factors associated with variability in this use in the Systemic Lupus International Collaborating Clinics Inception Cohort
Little J; Parker B; Lunt M; Hanly JG; Urowitz MB; Clarke AE; Romero-Diaz J; Gordon C; Bae S-C; Bernatsky S; Wallace DJ; Merrill JT; Buyon J; Isenberg DA; Rahman A; Ginzler EM; Petri M; Dooley MA; Fortin P; Gladman DD; Steinsson K; Ramsey-Goldman R; Khamashta MA; Aranow C; Mackay M; Alarcon GS; Manzi S; Nived O; Jonsen A; Zoma AA; van Vollenhoven RF; Ramos-Casals M; Ruiz-Irastorza G; Lim SS; Kalunian KC; Inanc M; Kamen DL; Peschken CA; Jacobsen S; Askanase A; Sanchez-Guerrero J; Bruce IN
Article: SCANDINAVIAN JOURNAL OF RHEUMATOLOGY. 2018;47(2):131-140
Relationship between glucocorticoid dose and adverse events in systemic lupus erythematosus: data from a randomized clinical trial
Emamikia S; Gentline C; Chatzidionysiou K; Arnaud L; van Vollenhoven R
Article: ARTHRITIS CARE AND RESEARCH. 2018;70(2):205-212
Dietary Intake of Polyunsaturated Fatty Acids and Pain in Spite of Inflammatory Control Among Methotrexate-Treated Early Rheumatoid Arthritis Patients
Lourdudoss C; Di Giuseppe D; Wolk A; Westerlind H; Klareskog L; Alfredsson L; van Vollenhoven RF; Lampa J
Article: CLINICAL AND EXPERIMENTAL RHEUMATOLOGY. 2018;36(1):21-28
Rheumatologists' guideline adherence in rheumatoid arthritis: a randomised controlled study on electronic decision support, education and feedback
Lesuis N; van Vollenhoven RF; Akkermans RP; Verhoef LM; Hulscher ME; den Broeder AA
Article: ARTHRITIS CARE AND RESEARCH. 2018;70(1):98-103
Study of Flare Assessment in Systemic Lupus Erythematosus Based on Paper Patients
Isenberg D; Sturgess J; Allen E; Aranow C; Askanase A; Sang-Cheol B; Bernatsky S; Bruce I; Buyon J; Cervera R; Clarke A; Dooley MA; Fortin P; Ginzler E; Gladman D; Hanly J; Inanc M; Jacobsen S; Kamen D; Khamashta M; Lim S; Manzi S; Nived O; Peschken C; Petri M; Kalunian K; Rahman A; Ramsey-Goldman R; Romero-Diaz J; Ruiz-Irastorza G; Sanchez-Guerrero J; Steinsson K; Sturfelt G; Urowitz M; van Vollenhoven R; Wallace DJ; Zoma A; Merrill J; Gordon C
Article: LUPUS SCIENCE AND MEDICINE. 2018;5(1):e000287
Predictors of persistent disease activity and long quiescence in systemic lupus erythematosus: results from the Hopkins Lupus Cohort
Giannakou I; Chatzidionysiou K; Magder LS; Gyori N; van Vollenhoven R; Petri MA
Article: ARTHRITIS RESEARCH & THERAPY. 2017;19(1):287
Nitrated nucleosome levels and neuropsychiatric events in systemic lupus erythematosus; a multi-center retrospective case-control study
Ferreira I; Croca S; Raimondo MG; Matharu M; Miller S; Giles I; Isenberg D; Ioannou Y; Hanly JG; Urowitz MB; Anderson N; Aranow C; Askanase A; Bae S-C; Bernatsky S; Bruce IN; Buyon J; Clarke AE; Dooley MA; Fortin P; Ginzler E; Gladman D; Gordon C; Inanc M; Jacobsen S; Kalunian K; Kamen D; Khamashta M; Lim S; Manzi S; Merrill J; Nived O; Peschken C; Petri M; Ramsey-Goldman R; Ruiz-Irastorza G; Sanchez-Guerrero J; Steinson K; Sturfelt GK; van Vollenhoven R; Wallace DJ; Zoma A; Rahman A
Article: ARTHRITIS & RHEUMATOLOGY. 2017;69(9):1751-1761
Transaminase Levels and Hepatic Events During Tocilizumab Treatment Pooled Analysis of Long-Term Clinical Trial Safety Data in Rheumatoid Arthritis
Genovese MC; Kremer JM; van Vollenhoven RF; Alten R; Jose Scali J; Kelman A; Dimonaco S; Brockwell L
Article: LUPUS. 2017;26(10):1051-1059
The prevalence and determinants of anti-DFS70 autoantibodies in an international inception cohort of systemic lupus erythematosus patients
Choi MY; Clarke AE; St Pierre Y; Hanly JG; Urowitz MB; Romero-Diaz J; Gordon C; Bae S-C; Bernatsky S; Wallace DJ; Merrill JT; Isenberg DA; Rahman A; Ginzler EM; Petri M; Bruce IN; Dooley MA; Fortin P; Gladman DD; Sanchez-Guerrero J; Steinsson K; Ramsey-Goldman R; Khamashta MA; Aranow C; Alarcon GS; Manzi S; Nived O; Zoma AA; van Vollenhoven RF; Ramos-Casals M; Ruiz-Irastorza G; Lim SS; Kalunian KC; Inanc M; Kamen DL; Peschken CA; Jacobsen S; Askanase A; Buyon J; Mahler M; Fritzler MJ
Article: ANNALS OF THE RHEUMATIC DISEASES. 2017;76(7):1279-1284
Tocilizumab combination therapy or monotherapy or methotrexate monotherapy in methotrexate-naive patients with early rheumatoid arthritis: 2-year clinical and radiographic results from the randomised, placebo-controlled FUNCTION trial
Burmester GR; Rigby WF; van Vollenhoven RF; Kay J; Rubbert-Roth A; Blanco R; Kadva A; Dimonaco S
Article: BMJ OPEN. 2017;7(6):e016154
Are dietary vitamin D, omega-3 fatty acids and folate associated with treatment results in patients with early rheumatoid arthritis? Data from a Swedish population-based prospective study
Lourdudoss C; Wolk A; Nise L; Alfredsson L; van Vollenhoven R
Article: RHEUMATOLOGY AND THERAPY. 2017;4(1):57-69
Long-Term Maintenance of Certolizumab Pegol Safety and Efficacy, in Combination with Methotrexate and as Monotherapy, in Rheumatoid Arthritis Patients
Fleischmann R; van Vollenhoven RF; Vencovsky J; Alten R; Davies O; Mountian I; de Longueville M; Carter D; Choy E
Article: SCANDINAVIAN JOURNAL OF RHEUMATOLOGY. 2017;46(3):241-246
Choosing wisely in daily practice: a mixed methods study on determinants of antinuclear antibody testing by rheumatologists
Lesuis N; den Broeder AA; van Vollenhoven RF; Vriezekolk JE; Hulscher MEJL
Article: ARTHRITIS & RHEUMATOLOGY. 2017;69(5):953-963
A Multi-Biomarker Disease Activity Score and the Choice of Second-Line Therapy in Early Rheumatoid Arthritis After Methotrexate Failure
Hambardzumyan K; Saevarsdottir S; Forslind K; Petersson IF; Wallman JK; Ernestam S; Bolce RJ; van Vollenhoven RF
Article: CLINICAL AND EXPERIMENTAL RHEUMATOLOGY. 2017;35(3):379-383
The effects of an educational meeting and subsequent computer reminders on the ordering of laboratory tests by rheumatologists: an interrupted time series analysis
Lesuis N; den Broeder N; Boers N; Piek E; Teerenstra S; Hulscher M; van Vollenhoven R; den Broeder AA
Article: TRIALS. 2017;18(1):161
Head-to-head comparison of aggressive conventional therapy and three biological treatments and comparison of two de-escalation strategies in patients who respond to treatment: study protocol for a multicenter, randomized, open-label, blinded-assessor, phase 4 study
Glinatsi D; Heiberg MS; Rudin A; Nordstrom D; Haavardsholm EA; Gudbjornsson B; Ostergaard M; Uhlig T; Grondal G; Horslev-Petersen K; van Vollenhoven R; Hetland ML
Article: RHEUMATOLOGY. 2017;56(4):541-549
Effect of tocilizumab on neutrophils in adult patients with rheumatoid arthritis: pooled analysis of data from phase 3 and 4 clinical trials
Moots RJ; Sebba A; Rigby W; Ostor A; Porter-Brown B; Donaldson F; Dimonaco S; Rubbert-Roth A; van Vollenhoven R; Genovese MC
Article: SCANDINAVIAN JOURNAL OF RHEUMATOLOGY. 2017;46(2):152-155
Implementation of protocolized tight control and biological dose optimization in daily clinical practice: results of a pilot study
Lesuis N; Verhoef LM; Nieboer LM; Bruyn GA; Baudoin P; van Vollenhoven RF; Hulscher MEJL; van den Hoogen FHJ; den Broeder AA
Article: ANNALS OF THE RHEUMATIC DISEASES. 2017;76(3):554-561
A framework for remission in SLE: consensus findings from a large international task force on definitions of remission in SLE (DORIS)
van Vollenhoven R; Voskuyl A; Bertsias G; Aranow C; Aringer M; Arnaud L; Askanase A; Balazova P; Bonfa E; Bootsma H; Boumpas D; Bruce I; Cervera R; Clarke A; Coney C; Costedoat-Chalumeau N; Czirjak L; Derksen R; Doria A; Doerner T; Fischer-Betz R; Fritsch-Stork R; Gordon C; Graninger W; Gyori N; Houssiau F; Isenberg D; Jacobsen S; Jayne D; Kuhn A; Le Guern V; Lerstrom K; Levy R; Machado-Ribeiro F; Mariette X; Missaykeh J; Morand E; Mosca M; Inanc M; Navarra S; Neumann I; Olesinska M; Petri M; Rahman A; Rekvig OP; Rovensky J; Shoenfeld Y; Smolen J; Tincani A; Urowitz M; van Leeuw B; Vasconcelos C; Voss A; Werth VP; Zakharova H; Zoma A; Schneider M; Ward M
Article: JOURNAL OF RHEUMATOLOGY. 2017;44(2):162-169
Rituximab Retreatment in Rheumatoid Arthritis in a Real-life Cohort: Data from the CERERRA Collaboration
Chatzidionysiou K; Lie E; Lukina G; Hetland ML; Hauge E-M; Pavelka K; Gabay C; Scherer A; Nordstrom D; Canhao H; Santos MJ; Tomsic M; Rotar Z; Victoria Hernandez M; Gomez-Reino J; Ancuta I; Kvien TK; van Vollenhoven R
Article: RMD OPEN. 2017;3(2):e000458
Obesity is a strong predictor of worse clinical outcomes and treatment responses in early rheumatoid arthritis: results from the SWEFOT trial.
Levitsky A; Brismar K; Hafström I; Hambardzumyan K; Lourdudoss C; van Vollenhoven RF; Saevarsdottir S
Article: RMD OPEN. 2017;3(1):e000369
Fully automated joint space width measurement and digital X-ray radiogrammetry in early RA.
Platten M; Kisten Y; Kälvesten J; Arnaud L; Forslind K; van Vollenhoven R
Article: RMD OPEN. 2017;67(1):e000371
A Systematic Review and Network Meta-Analysis on the Efficacy of Tumor Necrosis Factor Inhibitor-Methotrexate Combination Therapy Versus Triple Therapy in Methotrexate-Naive Patients with Rheumatoid Arthritis
Fleischmann R; Pope JE; Tongbram V; Tang D; Chung J; Collier D; Urs S; Ndirangu K; Wells GA; van Vollenhoven RF
Article: ANNALS OF THE RHEUMATIC DISEASES. 2017;76(1):96-104
Certolizumab pegol in combination with dose-optimised methotrexate in DMARD-naive patients with early, active rheumatoid arthritis with poor prognostic factors: 1-year results from C-EARLY, a randomised, double-blind, placebo-controlled phase III study
Emery P; Bingham COIII; Burmester GR; Bykerk VP; Furst DE; Mariette X; van der Heijde D; van Vollenhoven R; Arendt C; Mountian I; Purcaru O; Tatla D; VanLunen B; Weinblatt ME
Article: LUPUS SCIENCE AND MEDICINE. 2017;4(1):e000192
Disease activity patterns over time in patients with SLE: analysis of the Hopkins Lupus Cohort.
Györi N; Giannakou I; Chatzidionysiou K; Magder L; van Vollenhoven RF; Petri M
Article: ANNALS OF THE RHEUMATIC DISEASES. 2017;76(1):126-132
Economic considerations and patients' preferences affect treatment selection for patients with rheumatoid arthritis: a discrete choice experiment among European rheumatologists
Hifinger M; Hiligsmann M; Ramiro S; Watson V; Severens JL; Fautrel B; Uhlig T; van Vollenhoven R; Jacques P; Detert J; Canas da Silva J; Scire CA; Berghea F; Carmona L; Pentek M; Keat A; Boonen A
Article: LUPUS. 2016;25(14):1602-1609
Dietary micronutrient intake and atherosclerosis in systemic lupus erythematosus
Lourdudoss C; Elkan A-C; Hafstrom I; Jogestrand T; Gustafsson T; van Vollenhoven R; Frostegard J
Article: ARTHRITIS CARE AND RESEARCH. 2016;68(12):1758-1766
Infliximab Versus Conventional Combination Treatment and Seven-Year Work Loss in Early Rheumatoid Arthritis: Results of a Randomized Swedish Trial
Eriksson JK; Wallman JK; Miller H; Petersson IF; Ernestam S; Vivar N; van Vollenhoven RF; Neovius M
Article: CLINICAL AND EXPERIMENTAL RHEUMATOLOGY. 2016;34(6):1065-1071
Early treatment intensification induces favourable radiographic outcomes according to predicted versus observed radiographic progression in early rheumatoid arthritis: a subanalysis of the randomised FIN-RACo and NEO-RACo trials
Levitsky A; Wick MC; Mottonen T; Leirisalo-Repo M; Laasonen L; Korpela M; van Vollenhoven RF; Rantalaiho V
Article: ANNALS OF THE RHEUMATIC DISEASES. 2016;75(11):1939-1944
Disease activity-guided dose optimisation of adalimumab and etanercept is a cost-effective strategy compared with non-tapering tight control rheumatoid arthritis care: analyses of the DRESS study
Kievit W; van Herwaarden N; van den Hoogen FHJ; van Vollenhoven RF; Bijlsma JWJ; van den Bemt BJF; van der Maas A; den Broeder AA
Article: LUPUS. 2016;25(13):1420-1430
Safety, tolerability, efficacy and pharmacodynamics of the selective JAK1 inhibitor GSK2586184 in patients with systemic lupus erythematosus
Kahl L; Patel J; Layton M; Binks M; Hicks K; Leon G; Hachulla E; Machado D; Staumont-Salle D; Dickson M; Condreay L; Schifano L; Zamuner S; van Vollenhoven RF
Article: ARTHRITIS & RHEUMATOLOGY. 2016;68(9):2174-2183
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Treatment With Sirukumab (CNTO 136) in Patients With Active Lupus Nephritis
Rovin BH; van Vollenhoven RF; Aranow C; Wagner C; Gordon R; Zhuang Y; Belkowski S; Hsu B
Article: ARTHRITIS & RHEUMATOLOGY. 2016;68(8):1932-1944
A Longitudinal Analysis of Outcomes of Lupus Nephritis in an International Inception Cohort Using a Multistate Model Approach
Hanly JG; Su L; Urowitz MB; Romero-Diaz J; Gordon C; Bae S-C; Bernatsky S; Clarke AE; Wallace DJ; Merrill JT; Isenberg DA; Rahman A; Ginzler EM; Petri M; Bruce IN; Dooley MA; Fortin P; Gladman DD; Sanchez-Guerrero J; Steinsson K; Ramsey-Goldman R; Khamashta MA; Aranow C; Alarcon GS; Fessler BJ; Manzi S; Nived O; Sturfelt GK; Zoma AA; van Vollenhoven RF; Ramos-Casals M; Ruiz-Irastorza G; Lim SS; Kalunian KC; Inanc M; Kamen DL; Peschken CA; Jacobsen S; Askanase A; Theriault C; Farewell V
Article: ANNALS OF THE RHEUMATIC DISEASES. 2016;75(7):1336-1342
Effectiveness of tocilizumab with and without synthetic disease-modifying antirheumatic drugs in rheumatoid arthritis: results from a European collaborative study
Gabay C; Riek M; Hetland ML; Hauge E-M; Pavelka K; Tomsic M; Canhao H; Chatzidionysiou K; Lukina G; Nordstrom DC; Lie E; Ancuta I; Victoria Hernandez M; van Riel PLMC; van Vollenhoven R; Kvien TK
Article: ARTHRITIS RESEARCH & THERAPY. 2016;18:145
Switching from adalimumab to tofacitinib in the treatment of patients with rheumatoid arthritis
Genovese MC; van Vollenhoven RF; Wilkinson B; Wang L; Zwillich SH; Gruben D; Biswas P; Riese R; Takiya L; Jones TV
Article: NATURE REVIEWS DISEASE PRIMERS. 2016;2:16039
Systemic lupus erythematosus
Kaul A; Gordon C; Crow MK; Touma Z; Urowitz MB; van Vollenhoven R; Ruiz-Irastorza G; Hughes G
Article: PRESSE MEDICALE. 2016;45(6):e179-e192
New therapeutic approaches in rheumatoid arthritis
van Vollenhoven RF
Article: LUPUS. 2016;25(7):699-709
Long-term organ damage accrual and safety in patients with SLE treated with belimumab plus standard of care
Bruce IN; Urowitz M; van Vollenhoven R; Aranow C; Fettiplace J; Oldham M; Wilson B; Molta C; Roth D; Gordon D
Article: RHEUMATOLOGY. 2016;55(6):1031-1041
Tofacitinib or adalimumab versus placebo: patient-reported outcomes from a phase 3 study of active rheumatoid arthritis
Strand V; van Vollenhoven RF; Lee EB; Fleischmann R; Zwillich SH; Gruben D; Koncz T; Wilkinson B; Wallenstein G
Article: ANNALS OF THE RHEUMATIC DISEASES. 2016;75(6):1081-1091
Tocilizumab in early progressive rheumatoid arthritis: FUNCTION, a randomised controlled trial
Burmester GR; Rigby WF; van Vollenhoven RF; Kay J; Rubbert-Roth A; Kelman A; Dimonaco S; Mitchell N
Article: RHEUMATOLOGY. 2016;55(4):729-734
Does disease activity at start of biologic therapy influence work-loss in RA patients?
Olofsson T; Johansson K; Eriksson JK; van Vollenhoven R; Miller H; Petersson IF; Askling J; Neovius M
Article: ARTHRITIS CARE AND RESEARCH. 2016;68(4):562-569
Choosing Wisely in Daily Practice: An Intervention Study on Antinuclear Antibody Testing by Rheumatologists
Lesuis N; Hulscher MEJL; Piek E; Demirel H; van der Laan-Baalbergen N; Meek I; van Vollenhoven RF; den Broeder AA
Article: ARTHRITIS RESEARCH & THERAPY. 2016;18:50
Effectiveness of two different doses of rituximab for the treatment of rheumatoid arthritis in an international cohort: data from the CERERRA collaboration
Chatzidionysiou K; Lie E; Nasonov E; Lukina G; Hetland ML; Tarp U; Ancuta I; Pavelka K; Nordstrom DC; Gabay C; Canhao H; Tomsic M; van Riel PLCM; Gomez-Reino J; Kvien TK; van Vollenhoven RF
Article: RHEUMATOLOGY. 2016;55(2):252-262
The frequency and outcome of lupus nephritis: results from an international inception cohort study
Hanly JG; O'Keeffe AG; Su L; Urowitz MB; Romero-Diaz J; Gordon C; Bae S-C; Bernatsky S; Clarke AE; Wallace DJ; Merrill JT; Isenberg DA; Rahman A; Ginzler EM; Fortin P; Gladman DD; Sanchez-Guerrero J; Petri M; Bruce IN; Dooley MA; Ramsey-Goldman R; Aranow C; Alarcon GS; Fessler BJ; Steinsson K; Nived O; Sturfelt GK; Manzi S; Khamashta MA; van Vollenhoven RF; Zoma AA; Ramos-Casals M; Ruiz-Irastorza G; Lim SS; Stoll T; Inanc M; Kalunian KC; Kamen DL; Maddison P; Peschken CA; Jacobsen S; Askanase A; Theriault C; Thompson K; Farewell V
Article: RHEUMATOLOGY. 2016;55(2):230-236
Rituximab done: what's next in rheumatoid arthritis? A European observational longitudinal study assessing the effectiveness of biologics after rituximab treatment in rheumatoid arthritis
Walker UA; Jaeger VK; Chatzidionysiou K; Hetland ML; Hauge E-M; Pavelka K; Nordstrom DC; Canhao H; Tomsic M; van Vollenhoven R; Gabay C
Article: ANNALS OF THE RHEUMATIC DISEASES. 2016;75(2):356-361
Changes in the anticitrullinated peptide antibody response in relation to therapeutic outcome in early rheumatoid arthritis: results from the SWEFOT trial
Kastbom A; Forslind K; Ernestam S; Geborek P; Karlsson JA; Petersson IF; Saevarsdottir S; Klareskog L; van Vollenhoven RF; Lundberg K
Article: ANNALS OF THE RHEUMATIC DISEASES. 2016;75(2):332-340
Efficacy and safety of subcutaneous tabalumab, a monoclonal antibody to B-cell activating factor, in patients with systemic lupus erythematosus: results from ILLUMINATE-2, a 52-week, phase III, multicentre, randomised, double-blind, placebo-controlled study
Merrill JT; van Vollenhoven RF; Buyon JP; Furie RA; Stohl W; Morgan-Cox M; Dickson C; Anderson PW; Lee C; Berclaz P-Y; Doerner T
Article: RMD OPEN. 2016;2(1):e000133
A multicentre, randomised, controlled, open-label pilot study on the feasibility of discontinuation of adalimumab in established patients with rheumatoid arthritis in stable clinical remission.
Chatzidionysiou K; Turesson C; Teleman A; Knight A; Lindqvist E; Larsson P; Cöster L; Forslind K; van Vollenhoven R; Heimbürger M
Article: RMD OPEN. 2016;2(1):e000213
Malignancy rates in patients with rheumatoid arthritis treated with tocilizumab.
Rubbert-Roth A; Sebba A; Brockwell L; Kelman A; Porter-Brown B; Pulley J; Napalkov P; van Vollenhoven RF
Article: RMD OPEN. 2016;2(1):e000195
Practice what you preach? An exploratory multilevel study on rheumatoid arthritis guideline adherence by rheumatologists.
Lesuis N; den Broeder AA; Hulscher MEJL; van Vollenhoven RF
Article: RMD OPEN. 2016;2(1):e000197
Association of a multibiomarker disease activity score at multiple time-points with radiographic progression in rheumatoid arthritis: results from the SWEFOT trial.
Hambardzumyan K; Bolce RJ; Saevarsdottir S; Forslind K; Wallman JK; Cruickshank SE; Sasso EH; Chernoff D; van Vollenhoven RF
Article: RMD OPEN. 2016;2(2):e000323
Induction maintenance with tumour necrosis factor-inhibitor combination therapy with discontinuation versus methotrexate monotherapy in early rheumatoid arthritis: a systematic review and meta-analysis of efficacy in randomised controlled trials.
Emamikia S; Arkema EV; Györi N; Detert J; Chatzidionysiou K; Dougados M; Burmester GR; van Vollenhoven R
Article: LUPUS SCIENCE AND MEDICINE. 2016;3(1):e000163
Off-label use of rituximab for systemic lupus erythematosus in Europe.
Rydén-Aulin M; Boumpas D; Bultink I; Callejas Rubio JL; Caminal-Montero L; Castro A; Colodro Ruiz A; Doria A; Dörner T; Gonzalez-Echavarri C; Gremese E; Houssiau FA; Huizinga T; Inanç M; Isenberg D; Iuliano A; Jacobsen S; Jimenéz-Alonso J; Kovács L; Mariette X; Mosca M; Nived O; Oristrell J; Ramos-Casals M; Rascón J; Ruiz-Irastorza G; Sáez-Comet L; Salvador Cervelló G; Sebastiani GD; Squatrito D; Szücs G; Voskuyl A; van Vollenhoven R
Article: LUPUS SCIENCE AND MEDICINE. 2016;3(1):e000143
Cardiovascular events prior to or early after diagnosis of systemic lupus erythematosus in the systemic lupus international collaborating clinics cohort.
Urowitz MB; Gladman DD; Anderson NM; Su J; Romero-Diaz J; Bae SC; Fortin PR; Sanchez-Guerrero J; Clarke A; Bernatsky S; Gordon C; Hanly JG; Wallace DJ; Isenberg D; Rahman A; Merrill J; Ginzler E; Alarcón GS; Fessler BF; Petri M; Bruce IN; Khamashta M; Aranow C; Dooley M; Manzi S; Ramsey-Goldman R; Sturfelt G; Nived O; Steinsson K; Zoma A; Ruiz-Irastorza G; Lim S; Kalunian KC; Ỉnanç M; van Vollenhoven R; Ramos-Casals M; Kamen DL; Jacobsen S; Peschken C; Askanase A; Stoll T
Article: LUPUS SCIENCE AND MEDICINE. 2016;3(1):e000135
The association between diet and glucocorticoid treatment in patients with SLE.
Lourdudoss C; Hafström I; Frostegård J; van Vollenhoven R
Article: PLOS ONE. 2016;11(6):e0157961
Safety of Repeated Open-Label Treatment Courses of Intravenous Ofatumumab, a Human Anti-CD20 Monoclonal Antibody, in Rheumatoid Arthritis: Results from Three Clinical Trials
Quattrocchi E; Ostergaard M; Taylor PC; van Vollenhoven RF; Chu M; Mallett S; Perry H; Kurrasch R
Article: ARTHRITIS & RHEUMATOLOGY. 2016;68(1):46-55
VX-509 (Decernotinib), an Oral Selective JAK-3 Inhibitor, in Combination With Methotrexate in Patients With Rheumatoid Arthritis
Genovese MC; van Vollenhoven RF; Pacheco-Tena C; Zhang Y; Kinnman N
Article: ANNALS OF THE RHEUMATIC DISEASES. 2016;75(1):52-58
Full dose, reduced dose or discontinuation of etanercept in rheumatoid arthritis
van Vollenhoven RF; Ostergaard M; Leirisalo-Repo M; Uhlig T; Jansson M; Larsson E; Brock F; Franck-Larsson K
Article: JOURNAL OF RHEUMATOLOGY. 2015;42(12):2288-2295
Safety and Efficacy of Belimumab to Treat Systemic Lupus Erythematosus in Academic Clinical Practices
Hui-Yuen JS; Reddy A; Taylor J; Li X; Eichenfield AH; Bermudez LM; Starr AJ; Imundo LF; Buyon J; Furie RA; Kamen DL; Manzi S; Petri M; Ramsey-Goldman R; van Vollenhoven RF; Wallace DJ; Askanase A
Article: ARTHRITIS RESEARCH & THERAPY. 2015;17:325
Twenty-eight-week results from the REALISTIC phase IIIb randomized trial: efficacy, safety and predictability of response to certolizumab pegol in a diverse rheumatoid arthritis population
Weinblatt ME; Fleischmann R; van Vollenhoven RF; Emery P; Huizinga TWJ; Cutolo M; van der Heijde D; Duncan B; Davies O; Luijtens K; Dougados M
Article: SCANDINAVIAN JOURNAL OF RHEUMATOLOGY. 2015;44(6):431-437
Effectiveness and survival-on-drug of certolizumab pegol in rheumatoid arthritis in clinical practice: results from the national Swedish register
Chatzidionysiou K; Kristensen L-E; Eriksson J; Askling J; van Vollenhoven R
Article: ARTHRITIS & RHEUMATOLOGY. 2015;67(11):2855-2860
Enhancement of Patient Recruitment in Rheumatoid Arthritis Clinical Trials Using a Multi-Biomarker Disease Activity Score as an Inclusion Criterion
van Vollenhoven RF; Bolce R; Hambardzumyan K; Saevarsdottir S; Forslind K; Petersson IF; Sasso EH; Hwang CC; Segurado OG; Geborek P
Article: ARTHRITIS & RHEUMATOLOGY. 2015;67(11):2828-2836
Safety and Efficacy of Atacicept in Combination With Rituximab for Reducing the Signs and Symptoms of Rheumatoid Arthritis: A Phase II, Randomized, Double-Blind, Placebo-Controlled Pilot Trial
van Vollenhoven RF; Wax S; Li Y; Tak PP
Article: JOURNAL OF RHEUMATOLOGY. 2015;42(10):1761-1766
Longterm Safety of Rituximab: Final Report of the Rheumatoid Arthritis Global Clinical Trial Program over 11 Years
van Vollenhoven RF; Fleischmann RM; Furst DE; Lacey S; Lehane PB
Article: BMC MEDICINE. 2015;13:247
Serum survivin predicts responses to treatment in active rheumatoid arthritis: a post hoc analysis from the SWEFOT trial
Levitsky A; Erlandsson MC; van Vollenhoven RF; Bokarewa MI
Article: ARTHRITIS RESEARCH & THERAPY. 2015;17(1):245
Certolizumab pegol plus methotrexate 5-year results from the rheumatoid arthritis prevention of structural damage (RAPID) 2 randomized controlled trial and long-term extension in rheumatoid arthritis patients
Smolen JS; van Vollenhoven R; Kavanaugh A; Strand V; Vencovsky J; Schiff M; Landewe R; Haraoui B; Arendt C; Mountian I; Carter D; van der Heijde D
Article: SCANDINAVIAN JOURNAL OF RHEUMATOLOGY. 2015;44(5):348-353
Predicted vs. observed radiographic progression in early rheumatoid arthritis (POPeRA): results from a randomized trial
Levitsky A; Forslind K; van Vollenhoven RF
Article: ANNALS OF THE RHEUMATIC DISEASES. 2015;74(9):1706-1713
Factors associated with damage accrual in patients with systemic lupus erythematosus: results from the Systemic Lupus International Collaborating Clinics (SLICC) Inception Cohort
Bruce IN; O'Keeffe AG; Farewell V; Hanly JG; Manzi S; Su L; Gladman DD; Bae S-C; Sanchez-Guerrero J; Romero-Diaz J; Gordon C; Wallace DJ; Clarke AE; Bernatsky S; Ginzler EM; Isenberg DA; Rahman A; Merrill JT; Alarcon GS; Fessler BJ; Fortin PR; Petri M; Steinsson K; Dooley MA; Khamashta MA; Ramsey-Goldman R; Zoma AA; Sturfelt GK; Nived O; Aranow C; Mackay M; Ramos-Casals M; van Vollenhoven RF; Kalunian KC; Ruiz-Irastorza G; Lim S; Kamen DL; Peschken CA; Inanc M; Urowitz MB
Article: ARTHRITIS CARE AND RESEARCH. 2015;67(9):1237-1245
Treatment Algorithms in Systemic Lupus Erythematosus
Muangchan C; van Vollenhoven RF; Bernatsky SR; Smith CD; Hudson M; Inanc M; Rothfield NF; Nash PT; Furie RA; Senecal J-L; Chandran V; Burgos-Vargas R; Ramsey-Goldman R; Pope JE
Article: ANNALS OF THE RHEUMATIC DISEASES. 2015;74(8):1567-1570
Efficacy and safety of tabalumab, an anti-B-cell-activating factor monoclonal antibody, in patients with rheumatoid arthritis who had an inadequate response to methotrexate therapy: results from a phase III multicentre, randomised, double-blind study
Smolen JS; Weinblatt ME; van der Heijde D; Rigby WFC; van Vollenhoven R; Bingham COIII; Veenhuizen M; Gill A; Zhao F; Komocsar WJ; Berclaz P-Y; Ortmann R; Lee C
Article: ANNALS OF THE RHEUMATIC DISEASES. 2015;74(8):1509-1514
Current smoking status is a strong predictor of radiographic progression in early rheumatoid arthritis: results from the SWEFOT trial
Saevarsdottir S; Rezaei H; Geborek P; Petersson I; Ernestam S; Albertsson K; Forslind K; van Vollenhoven RF
Article: RHEUMATOLOGY. 2015;54(8):1472-1477
Does disease activity at the start of biologic therapy influence health care costs in patients with RA?
Johansson K; Eriksson JK; van Vollenhoven R; Miller H; Askling J; Neovius M
Article: ANNALS OF THE RHEUMATIC DISEASES. 2015;74(8):1530-1536
Impact of early disease factors on metabolic syndrome in systemic lupus erythematosus: data from an international inception cohort
Parker B; Urowitz MB; Gladman DD; Lunt M; Donn R; Bae S-C; Sanchez-Guerrero J; Romero-Diaz J; Gordon C; Wallace DJ; Clarke AE; Bernatsky S; Ginzler EM; Isenberg DA; Rahman A; Merrill JT; Alarcon GS; Fessler BJ; Fortin PR; Hanly JG; Petri M; Steinsson K; Dooley MA; Manzi S; Khamashta MA; Ramsey-Goldman R; Zoma AA; Sturfelt GK; Nived O; Aranow C; Mackay M; Ramos-Casals M; van Vollenhoven RF; Kalunian KC; Ruiz-Irastorza G; Lim SS; Kamen DL; Peschken CA; Inanc M; Bruce IN
Article: ARTHRITIS & RHEUMATOLOGY. 2015;67(7):1837-1847
Mood Disorders in Systemic Lupus Erythematosus: Results From an International Inception Cohort Study
Hanly JG; Su L; Urowitz MB; Romero-Diaz J; Gordon C; Bae S-C; Bernatsky S; Clarke AE; Wallace DJ; Merrill JT; Isenberg DA; Rahman A; Ginzler EM; Petri M; Bruce IN; Dooley MA; Fortin P; Gladman DD; Sanchez-Guerrero J; Steinsson K; Ramsey-Goldman R; Khamashta MA; Aranow C; Alarcon GS; Fessler BJ; Manzi S; Nived O; Sturfelt GK; Zoma AA; van Vollenhoven RF; Ramos-Casals M; Ruiz-Irastorza G; Lim SS; Kalunian KC; Inanc M; Kamen DL; Peschken CA; Jacobsen S; Askanase A; Theriault C; Thompson K; Farewell V
Article: ANNALS OF THE RHEUMATIC DISEASES. 2015;74(6):1102-1109
Pretreatment multi-biomarker disease activity score and radiographic progression in early RA: results from the SWEFOT trial
Hambardzumyan K; Bolce R; Saevarsdottir S; Cruickshank SE; Sasso EH; Chernoff D; Forslind K; Petersson IF; Geborek P; van Vollenhoven RF
Article: ANNALS OF THE RHEUMATIC DISEASES. 2015;74(6):1094-1101
Cost-effectiveness of infliximab versus conventional combination treatment in methotrexate-refractory early rheumatoid arthritis: 2-year results of the register-enriched randomised controlled SWEFOT trial
Eriksson JK; Karlsson JA; Bratt J; Petersson IF; van Vollenhoven RF; Ernestam S; Geborek P; Neovius M
Article: ANNALS OF THE RHEUMATIC DISEASES. 2015;74(5):890-896
Effectiveness of TNF inhibitor switch in RA: results from the national Swedish register
Chatzidionysiou K; Askling J; Eriksson J; Kristensen LE; van Vollenhoven R
Article: THE BMJ. 2015;350:h1389
Disease activity guided dose reduction and withdrawal of adalimumab or etanercept compared with usual care in rheumatoid arthritis: open label, randomised controlled, non-inferiority trial
van Herwaarden N; van der Maas A; Minten MJM; van den Hoogen FHJ; Kievit W; van Vollenhoven RF; Bijlsma JWJ; van den Bemt BJF; den Broeder AA
Article: RMD OPEN. 2015;1(1):e000044
The incidence of tuberculosis in patients treated with certolizumab pegol across indications: impact of baseline skin test results, more stringent screening criteria and geographic region.
Mariette X; Vencovsky J; Lortholary O; Gomez-Reino J; de Longueville M; Ralston P; Weinblatt M; van Vollenhoven R
Article: RMD OPEN. 2015;1(1):e000106
Detection of clinically manifest and silent synovitis in the hands and wrists by fluorescence optical imaging.
Kisten Y; Györi N; Af Klint E; Rezaei H; Levitsky A; Karlsson A; van Vollenhoven R
Article: LUPUS. 2015;24(1):42-49
Anti-C1q antibodies in systemic lupus erythematosus
Orbai A-M; Truedsson L; Sturfelt G; Nived O; Fang H; Alarcon GS; Gordon C; Merrill JT; Fortin PR; Bruce IN; Isenberg DA; Wallace DJ; Ramsey-Goldman R; Bae S-C; Hanly JG; Sanchez-Guerrero J; Clarke AE; Aranow CB; Manzi S; Urowitz MB; Gladman DD; Kalunian KC; Costner MI; Werth VP; Zoma A; Bernatsky S; Ruiz-Irastorza G; Khamashta MA; Jacobsen S; Buyon JP; Maddison P; Dooley MA; Van Vollenhoven RF; Ginzler E; Stoll T; Peschken C; Jorizzo JL; Callen JP; Lim SS; Fessler BJ; Inanc M; Kamen DL; Rahman A; Steinsson K; Franks AGJ; Sigler L; Hameed S; Pham N; Brey R; Weisman MH; McGwin GJ; Magder LS; Petri M
Article: ANNALS OF THE RHEUMATIC DISEASES. 2015;74(1):96-103
Update on the safety profile of certolizumab pegol in rheumatoid arthritis: an integrated analysis from clinical trials
Bykerk VP; Cush J; Winthrop K; Calabrese L; Lortholary O; de Longueville M; van Vollenhoven R; Mariette X
Article: ANNALS OF THE RHEUMATIC DISEASES. 2014;73(12):2094-2100
Long-term safety and efficacy of certolizumab pegol in combination with methotrexate in the treatment of rheumatoid arthritis: 5-year results from the RAPID 1 trial and open-label extension
Keystone E; Landewe R; van Vollenhoven R; Combe B; Strand V; Mease P; Shaughnessy L; VanLunen B; van der Heijde D
Article: ARTHRITIS RESEARCH & THERAPY. 2014;16(5):448
Diagnostic utility of musculoskeletal ultrasound in patients with suspected arthritis - a probabilistic approach
Rezaei H; Torp-Pedersen S; af Klint E; Backheden M; Kisten Y; Gyeri N; van Vollenhoven RF
Article: ARTHRITIS CARE AND RESEARCH. 2014;66(8):1167-1176
25-Hydroxyvitamin D and Cardiovascular Disease in Patients With Systemic Lupus Erythematosus: Data From a Large International Inception Cohort
Lertratanakul A; Wu P; Dyer A; Urowitz M; Gladman D; Fortin P; Bae S-C; Gordon C; Clarke A; Bernatsky S; Hanly JG; Isenberg D; Rahman A; Merrill J; Wallace DJ; Ginzler E; Khamashta M; Bruce I; Nived O; Sturfelt G; Steinsson K; Manzi S; Dooley MA; Kalunian K; Petri M; Aranow C; Font J; van Vollenhoven R; Stoll T; Ramsey-Goldman R
Article: NEW ENGLAND JOURNAL OF MEDICINE. 2014;370(25):2377-2386
Tofacitinib versus Methotrexate in Rheumatoid Arthritis
Lee EB; Fleischmann R; Hall S; Wilkinson B; Bradley JD; Gruben D; Koncz T; Krishnaswami S; Wallenstein GV; Zang C; Zwillich SH; van Vollenhoven RF
Article: CLINICAL AND EXPERIMENTAL RHEUMATOLOGY. 2014;32(3):390-394
Dose reduction of tocilizumab in rheumatoid arthritis patients with low disease activity
van Herwaarden N; Herfkens-Hol S; van der Maas A; van den Bemt BJF; van Vollenhoven RF; Bijlsma JWJ; den Broeder AA
Article: CLINICAL AND EXPERIMENTAL RHEUMATOLOGY. 2014;32(3):315-323
The early clinical course of infliximab treatment in rheumatoid arthritis: results from the REMARK observational study
Westhovens R; van Vollenhoven RF; Boumpas DT; Brzosko M; Svensson K; Bjorneboe O; Meeuwisse CM; Srinivasan S; Gaudin P; Smolen JS; Rahman MU; Nelissen RL; Vastesaeger N
Article: JOURNAL OF RHEUMATOLOGY. 2014;41(5):875-880
American College of Rheumatology Criteria at Inception, and Accrual over 5 Years in the SLICC Inception Cohort
Urowitz MB; Gladman DD; Ibanez D; Sanchez-Guerrero J; Romero-Diaz J; Gordon C; Bae S-C; Clarke AE; Bernatsky S; Fortin PR; Hanly JG; Isenberg D; Rahman A; Wallace DJ; Ginzler E; Petri M; Bruce IN; Merrill JT; Nived O; Sturfelt G; Dooley MA; Alarcon GS; Fessler B; Steinsson K; Ramsey-Goldman R; Zoma A; Khamashta M; Manzi S; van Vollenhoven R; Ramos-Casals M; Aranow C; Stoll T
Article: LUPUS. 2014;23(3):299-304
Mycophenolate mofetil in the treatment of SLE and systemic vasculitis: experience at a single university center
Lourdudoss C; van Vollenhoven R
Article: TRAVEL MEDICINE AND INFECTIOUS DISEASE. 2014;12(2):134-142
Hepatitis A vaccine for immunosuppressed patients with rheumatoid arthritis: A prospective, open-label, multi-centre study
Askling HH; Rombo L; van Vollenhoven R; Hallen I; Thorner A; Nordin M; Herzog C; Kantele A
Article: SCANDINAVIAN JOURNAL OF IMMUNOLOGY. 2014;79(2):149-155
Peripheral and Site-Specific CD4⁺CD28^null T Cells from Rheumatoid Arthritis Patients Show Distinct Characteristics
Pieper J; Johansson S; Snir O; Linton L; Rieck M; Buckner JH; Winqvist O; van Vollenhoven R; Malmstrom V
Article: THE LANCET. 2014;383(9914):321-332
Adjustment of therapy in rheumatoid arthritis on the basis of achievement of stable low disease activity with adalimumab plus methotrexate or methotrexate alone: the randomised controlled OPTIMA trial
Smolen JS; Emery P; Fleischmann R; van Vollenhoven RF; Pavelka K; Durez P; Guerette B; Kupper H; Redden L; Arora V; Kavanaugh A
Article: CURRENT RHEUMATOLOGY REPORTS. 2014;16(9):444
Rituximab and Lupus - A Promising Pair?
Eko SL; van Vollenhoven RF
Article: LUPUS SCIENCE AND MEDICINE. 2014;1(1):e000028
Editorial.
Buyon J; van Vollenhoven R
Article: LUPUS SCIENCE AND MEDICINE. 2014;1(1):e000033
Lupus Science and Medicine: the Editors present highlights for the bedside and for the bench in the inaugural issue.
Buyon J; van Vollenhoven R
Article: ANNALS OF THE RHEUMATIC DISEASES. 2013;72(12):1927-1933
Addition of infliximab compared with addition of sulfasalazine and hydroxychloroquine to methotrexate in early rheumatoid arthritis: 2-year quality-of-life results of the randomised, controlled, SWEFOT trial
Karlsson JA; Neovius M; Nilsson J-A; Petersson IF; Bratt J; van Vollenhoven RF; Ernestam S; Geborek P
Article: EUROPEAN JOURNAL OF HEALTH ECONOMICS. 2013;14(6):863-873
The cost-effectiveness of TNF-inhibitors for the treatment of rheumatoid arthritis in Swedish clinical practice
Lekander I; Borgstrom F; Lysholm J; van Vollenhoven RF; Lindblad S; Geborek P; Kobelt G
Article: ARTHRITIS & RHEUMATOLOGY. 2013;65(11):2887-2897
Headache in Systemic Lupus Erythematosus Results From a Prospective, International Inception Cohort Study
Hanly JG; Urowitz MB; O'Keeffe AG; Gordon C; Bae S-C; Sanchez-Guerrero J; Romero-Diaz J; Clarke AE; Bernatsky S; Wallace DJ; Ginzler EM; Isenberg DA; Rahman A; Merrill JT; Petri M; Fortin PR; Gladman DD; Fessler BJ; Alarcon GS; Bruce IN; Dooley MA; Steinsson K; Khamashta MA; Ramsey-Goldman R; Manzi S; Sturfelt GK; Nived O; Zoma AA; van Vollenhoven RF; Ramos-Casals M; Aranow C; Mackay M; Ruiz-Irastorza G; Kalunian KC; Lim SS; Inanc M; Kamen DL; Peschken CA; Jacobsen S; Theriault C; Thompson K; Farewell V
Article: BMC MUSCULOSKELETAL DISORDERS. 2013;14:299
Dose REduction strategy of subcutaneous TNF inhibitors in rheumatoid arthritis: design of a pragmatic randomised non inferiority trial, the DRESS study
den Broeder AA; van Herwaarden N; van der Maas A; van den Hoogen FHJ; Bijlsma JW; van Vollenhoven RF; van den Bemt BJF
Article: LUPUS. 2013;22(11):1118-1127
Health-related quality of life, fatigue and mood in patients with SLE and high levels of pain compared to controls and patients with low levels of pain
Waldheim E; Elkan A-C; Pettersson S; van Vollenhoven R; Bergman S; Frostegard J; Henriksson EW
Article: ARTHRITIS & RHEUMATOLOGY. 2013;65(10):2661-2671
Phase I, Randomized, Double-Blind, Placebo-Controlled, Multiple Intravenous, Dose-Ascending Study of Sirukumab in Cutaneous or Systemic Lupus Erythematosus
Szepietowski JC; Nilganuwong S; Wozniacka A; Kuhn A; Nyberg F; van Vollenhoven RF; Bengtsson AA; Reich A; de Vries DE; van Hartingsveldt B; Robinson DWJ; Gordon R; Hsu B
Article: ANNALS OF THE RHEUMATIC DISEASES. 2013;72(9):1496-1502
Long-term safety of rituximab in rheumatoid arthritis: 9.5-year follow-up of the global clinical trial programme with a focus on adverse events of interest in RA patients
van Vollenhoven RF; Emery P; Bingham COIII; Keystone EC; Fleischmann RM; Furst DE; Tyson N; Collinson N; Lehane PB
Article: JAMA INTERNAL MEDICINE. 2013;173(15):1407-1414
Biological vs Conventional Combination Treatment and Work Loss in Early Rheumatoid Arthritis A Randomized Trial
Eriksson JK; Neovius M; Bratt J; Petersson IF; van Vollenhoven RF; Geborek P; Ernestam S
Article: BMC IMMUNOLOGY. 2013;14:34
CTLA4-Ig (abatacept) therapy modulates T cell effector functions in autoantibody-positive rheumatoid arthritis patients
Pieper J; Herrath J; Raghavan S; Muhammad K; van Vollenhoven R; Malmstrm V
Article: ANNALS OF THE RHEUMATIC DISEASES. 2013;72(8):1308-1314
Clinical associations of the metabolic syndrome in systemic lupus erythematosus: data from an international inception cohort
Parker B; Urowitz MB; Gladman DD; Lunt M; Bae S-C; Sanchez-Guerrero J; Romero-Diaz J; Gordon C; Wallace DJ; Clarke AE; Bernatsky S; Ginzler EM; Isenberg DA; Rahman A; Merrill JT; Alarcon GS; Fessler BJ; Fortin PR; Hanly JG; Petri M; Steinsson K; Dooley M-A; Manzi S; Khamashta MA; Ramsey-Goldman R; Zoma AA; Sturfelt GK; Nived O; Aranow C; Mackay M; Ramos-Casals M; van Vollenhoven RF; Kalunian KC; Ruiz-Irastorza G; Lim S; Kamen DL; Peschken CA; Inanc M; Bruce IN
Article: ARTHRITIS & RHEUMATOLOGY. 2013;65(8):2143-2153
Baseline Predictors of Systemic Lupus Erythematosus Flares: Data From the Combined Placebo Groups in the Phase III Belimumab Trials
Petri MA; van Vollenhoven RF; Buyon J; Levy RA; Navarra SV; Cervera R; Zhong ZJ; Freimuth WW
Article: CLINICAL AND EXPERIMENTAL RHEUMATOLOGY. 2013;31(4):S82-S85
New drugs in systemic lupus erythematosus: when to start and when to stop
Mosca M; van Vollenhoven R
Article: ANNALS OF THE RHEUMATIC DISEASES. 2013;72(7):1156-1162
Association of joint space narrowing with impairment of physical function and work ability in patients with early rheumatoid arthritis: protection beyond disease control by adalimumab plus methotrexate
Smolen JS; van der Heijde DM; Keystone EC; van Vollenhoven RF; Goldring MB; Guerette B; Cifaldi MA; Chen N; Liu S; Landewe RBM
Article: LUPUS. 2013;22(8):793-801
Drivers of cost and health-related quality of life in patients with systemic lupus erythematosus (SLE): a Swedish nationwide study based on patient reports
Bexelius C; Wachtmeister K; Skare P; Jonsson L; van Vollenhoven R
Article: LUPUS. 2013;22(8):819-826
Limitations of current treatments for systemic lupus erythematosus: a patient and physician survey
Strand V; Galateanu C; Pushparajah DS; Nikai E; Sayers J; Wood R; van Vollenhoven RF
Article: JOURNAL OF RHEUMATOLOGY. 2013;40(6):768-780
Longterm Safety and Efficacy of Tocilizumab in Patients with Rheumatoid Arthritis: A Cumulative Analysis of Up to 4.6 Years of Exposure
Genovese MC; Rubbert-Roth A; Smolen JS; Kremer J; Khraishi M; Gomez-Reino J; Sebba A; Pilson R; Williams S; Van Vollenhoven R
Article: BEST PRACTICE AND RESEARCH: CLINICAL RHEUMATOLOGY. 2013;27(3):341-349
Biologics in SLE: Towards new approaches
van Vollenhoven RF; Parodis I; Levitsky A
Article: THE LANCET. 2013;381(9877):1541-1550
Tocilizumab monotherapy versus adalimumab monotherapy for treatment of rheumatoid arthritis (ADACTA): a randomised, double-blind, controlled phase 4 trial
Gabay C; Emery P; van Vollenhoven R; Dikranian A; Alten R; Pavelka K; Klearman M; Musselman D; Agarwal S; Green J; Kavanaugh A
Article: RHEUMATOLOGY. 2013;52(5):847-855
Long-term follow-up in lupus nephritis patients treated with rituximab-clinical and histopathological response
Jonsdottir T; Zickert A; Sundelin B; Henriksson EW; van Vollenhoven RF; Gunnarsson I
Article: BMC MUSCULOSKELETAL DISORDERS. 2013;14:79
Evaluation of hand bone loss by digital X-ray radiogrammetry as a complement to clinical and radiographic assessment in early rheumatoid arthritis: results from the SWEFOT trial
Rezaei H; Saevarsdottir S; Geborek P; Petersson IF; van Vollenhoven RF; Forslind K
Article: VALUE IN HEALTH. 2013;16(2):251-258
The Comparison of Trial Data-Based and Registry Data-Based Cost-Effectiveness of Infliximab Treatment for Rheumatoid Arthritis in Sweden Using a Modeling Approach
Lekander I; Kobelt G; Svarvar P; Ljung T; van Vollenhoven R; Borgstrom F
Article: LUPUS. 2013;22(2):144-154
Safety profile of belimumab: pooled data from placebo-controlled phase 2 and 3 studies in patients with systemic lupus erythematosus
Wallace DJ; Navarra S; Petri MA; Gallacher A; Thomas M; Furie R; Levy RA; van Vollenhoven RF; Cooper S; Zhong ZJ; Freimuth W; Cervera R
Article: LUPUS. 2013;22(2):136-143
Extent and characteristics of self-reported pain in patients with systemic lupus erythematosus
Waldheim E; Elkan A-C; Bergman S; Frostegard J; van Vollenhoven R; Henriksson EW
Article: SCANDINAVIAN JOURNAL OF RHEUMATOLOGY. 2013;42(3):190-195
Rituximab versus anti-TNF in patients who previously failed one TNF inhibitor in an observational cohort
Chatzidionysiou K; van Vollenhoven RF
Article: RHEUMATOLOGY. 2012;51(12):2204-2214
Efficacy and safety of certolizumab pegol in a broad population of patients with active rheumatoid arthritis: results from the REALISTIC phase IIIb study
Weinblatt ME; Fleischmann R; Huizinga TWJ; Emery P; Pope J; Massarotti EM; van Vollenhoven RF; Wollenhaupt J; Bingham COIII; Duncan B; Goel N; Davies OR; Dougados M
Article: ANNALS OF THE RHEUMATIC DISEASES. 2012;71(11):1865-1867
Incidence of progressive multifocal leukoencephalopathy in patients with rheumatoid arthritis: a national population-based study
Arkema EV; van Vollenhoven RF; Askling J
Article: JOURNAL OF RHEUMATOLOGY. 2012;39(10):2008-2011
Beneficial Effect of Interleukin 1 Inhibition with Anakinra in Adult-onset Still's Disease. An Open, Randomized, Multicenter Study
Nordstrom D; Knight A; Luukkainen R; van Vollenhoven R; Rantalaiho V; Kajalainen A; Brun JG; Proven A; Ljung L; Kautiainen H; Pettersson T
Article: RHEUMATOLOGY. 2012;51(9):1628-1638
Sustained efficacy of certolizumab pegol added to methotrexate in the treatment of rheumatoid arthritis: 2-year results from the RAPID 1 trial
Keystone EC; Combe B; Smolen J; Strand V; Goel N; van Vollenhoven R; Mease P; Landewe R; Fleischmann R; Luijtens K; van der Heijde D
Article: ANNALS OF THE RHEUMATIC DISEASES. 2012;71(9):1502-1509
Seizure disorders in systemic lupus erythematosus results from an international, prospective, inception cohort study
Hanly JG; Urowitz MB; Su L; Gordon C; Bae S-C; Sanchez-Guerrero J; Romero-Diaz J; Wallace DJ; Clarke AE; Ginzler EM; Merrill JT; Isenberg DA; Rahman A; Petri M; Fortin PR; Gladman DD; Bruce IN; Steinsson K; Dooley MA; Khamashta MA; Alarcon GS; Fessler BJ; Ramsey-Goldman R; Manzi S; Zoma AA; Sturfelt GK; Nived O; Aranow C; Mackay M; Ramos-Casals M; van Vollenhoven RF; Kalunian KC; Ruiz-Irastorza G; Lim S; Kamen DL; Peschken CA; Inanc M; Theriault C; Thompson K; Farewell V
Article: NEW ENGLAND JOURNAL OF MEDICINE. 2012;367(6):508-519
Tofacitinib or Adalimumab versus Placebo in Rheumatoid Arthritis
van Vollenhoven RF; Fleischmann R; Cohen S; Lee EB; Garcia Meijide JA; Wagner S; Forejtova S; Zwillich SH; Gruben D; Koncz T; Wallenstein GV; Krishnaswami S; Bradley JD; Wilkinson B
Article: ANNALS OF THE RHEUMATIC DISEASES. 2012;71(8):1343-1349
Belimumab in the treatment of systemic lupus erythematosus: high disease activity predictors of response
van Vollenhoven RF; Petri MA; Cervera R; Roth DA; Ji BN; Kleoudis CS; Zhong ZJ; Freimuth W
Article: CYTOKINE. 2012;59(2):392-399
Pregnancy-associated inflammatory markers are elevated in pregnant women with systemic lupus erythematosus
Bjorkander S; Bremme K; Persson J-O; van Vollenhoven RF; Sverremark-Ekstrom E; Holmlund U
Article: ARTHRITIS & RHEUMATOLOGY. 2012;64(8):2677-2686
Derivation and validation of the systemic lupus international collaborating clinics classification criteria for systemic lupus erythematosus
Petri M; Orbai A-M; Alarcon GS; Gordon C; Merrill JT; Fortin PR; Bruce IN; Isenberg D; Wallace DJ; Nived O; Sturfelt G; Ramsey-Goldman R; Bae S-C; Hanly JG; Sanchez-Guerrero J; Clarke A; Aranow C; Manzi S; Urowitz M; Gladman D; Kalunian K; Costner M; Werth VP; Zoma A; Bernatsky S; Ruiz-Irastorza G; Khamashta MA; Jacobsen S; Buyon JP; Maddison P; Dooley MA; van vollenhoven RF; Ginzler E; Stoll T; Peschken C; Jorizzo JL; Callen JP; Lim SS; Fessler BJ; Inanc M; Kamen DL; Rahman A; Steinsson K; Franks AGJ; Sigler L; Hameed S; Fang H; Ngoc P; Brey R; Weisman MH; McGwin GJ; Magder LS
Article: BMC MEDICINE. 2012;10:82
Gender and the treatment of immune-mediated chronic inflammatory diseases: rheumatoid arthritis, inflammatory bowel disease and psoriasis: an observational study
Lesuis N; Befrits R; Nyberg F; van Vollenhoven RF
Article: CLINICAL AND EXPERIMENTAL RHEUMATOLOGY. 2012;30(4):S112-S115
Treat-to-target in systemic lupus erythematosus: where are we today?
Mosca M; Boumpas D; Bruce IN; Cervera R; Czirjak L; Doerner T; Houssiau F; Jacobsen S; Schneider M; Smolen JS; Voskuyl AE; van Vollenhoven RF
Article: ANNALS OF THE RHEUMATIC DISEASES. 2012;71(7):1203-1206
Is there a sex bias in prescribing anti-tumour necrosis factor medications to patients with rheumatoid arthritis? A nation-wide cross-sectional study
Arkema EV; Neovius M; Joelsson JK; Simard JF; van Vollenhoven RF
Article: THE LANCET. 2012;379(9827):1712-1720
Conventional combination treatment versus biological treatment in methotrexate-refractory early rheumatoid arthritis: 2 year follow-up of the randomised, non-blinded, parallel-group Swefot trial
van Vollenhoven RF; Geborek P; Forslind K; Albertsson K; Ernestam S; Petersson IF; Chatzidionysiou K; Bratt J
Article: ARTHRITIS & RHEUMATOLOGY. 2012;64(5):1579-1588
Pharmacokinetics, tolerability, and preliminary efficacy of paquinimod (ABR-215757), a new quinoline-3-carboxamide derivative: Studies in lupus-prone mice and a multicenter, randomized, double-blind, placebo-controlled, repeat-dose, dose-ranging study in patients with systemic lupus erythematosus
Bengtsson AA; Sturfelt G; Lood C; Ronnblom L; van Vollenhoven RF; Axelsson B; Sparre B; Tuvesson H; Ohman MW; Leanderson T
Article: ARTHRITIS RESEARCH & THERAPY. 2012;14(3):R100
Anti-type II collagen antibodies are associated with early radiographic destruction in rheumatoid arthritis
Mullazehi M; Wick MC; Klareskog L; van Vollenhoven R; Ronnelid J
Article: ANNALS OF THE RHEUMATIC DISEASES. 2012;71(3):374-377
Effectiveness of disease-modifying antirheumatic drug co-therapy with methotrexate and leflunomide in rituximab-treated rheumatoid arthritis patients: results of a 1-year follow-up study from the CERERRA collaboration
Chatzidionysiou K; Lie E; Nasonov E; Lukina G; Hetland ML; Tarp U; van Riel PLCM; Nordstrom DC; Gomez-Reino J; Pavelka K; Tomsic M; Kvien TK; van Vollenhoven RF; Gabay C
Article: ANNALS OF THE RHEUMATIC DISEASES. 2012;71(3):351-357
Sustained inhibition of progressive joint damage with rituximab plus methotrexate in early active rheumatoid arthritis: 2-year results from the randomised controlled trial IMAGE
Tak PP; Rigby W; Rubbert-Roth A; Peterfy C; van Vollenhoven RF; Stohl W; Healy E; Hessey E; Reynard M; Shaw T
Article: ANNALS OF THE RHEUMATIC DISEASES. 2012;71(2):186-191
In early rheumatoid arthritis, patients with a good initial response to methotrexate have excellent 2-year clinical outcomes, but radiological progression is not fully prevented: data from the methotrexate responders population in the SWEFOT trial
Rezaei H; Saevarsdottir S; Forslind K; Albertsson K; Wallin H; Bratt J; Ernestam S; Geborek P; Petersson IF; van Vollenhoven RF
Article: BMJ OPEN. 2012;2(5):e001524
Influence of FCGR3A genotype on the therapeutic response to rituximab in rheumatoid arthritis: an observational cohort study
Kastbom A; Coster L; Arlestig L; Chatzidionysiou A; van Vollenhoven RF; Padyukov L; Rantapaa-Dahlqvist S; Saevarsdottir S
Article: PHARMACOGENETICS AND GENOMICS. 2012;22(1):1-9
Patterns of interaction between genetic and nongenetic attributes and methotrexate efficacy in rheumatoid arthritis
Dervieux T; Wessels JAM; Kremer JM; Padyukov L; Seddighzadeh M; Saevarsdottir S; van Vollenhoven RF; Klareskog L; Huizinga TW; Guchelaar H-J
Article: ARTHRITIS CARE AND RESEARCH. 2012;64(1):132-137
Evolution of disease burden over five years in a multicenter inception systemic lupus erythematosus cohort
Urowitz MB; Gladman DD; Ibanez D; Fortin PR; Bae SC; Gordon C; Clarke A; Bernatsky S; Hanly JG; Isenberg D; Rahman A; Sanchez-Guerrero J; Wallace DJ; Ginzler E; Alarcon GS; Merrill JT; Bruce IN; Sturfelt G; Nived O; Steinsson K; Khamashta M; Petri M; Manzi S; Ramsey-Goldman R; Dooley MA; van Vollenhoven RF; Ramos M; Stoll T; Zoma A; Kalunian K; Aranow C
Article: ARTHRITIS & RHEUMATOLOGY. 2011;63(12):3918-3930
A phase III, randomized, placebo-controlled study of belimumab, a monoclonal antibody that inhibits B lymphocyte stimulator, in patients with systemic lupus erythematosus
Furie R; Petri M; Zamani O; Cervera R; Wallace DJ; Tegzova D; Sanchez-Guerrero J; Schwarting A; Merrill JT; Chatham WW; Stohl W; Ginzler EM; Hough DR; Zhong ZJ; Freimuth W; van Vollenhoven RF
Article: ANNALS OF THE RHEUMATIC DISEASES. 2011;70(11):1895-1904
Malignancies associated with tumour necrosis factor inhibitors in registries and prospective observational studies: a systematic review and meta-analysis
Mariette X; Matucci-Cerinic M; Pavelka K; Taylor P; van Vollenhoven R; Heatley R; Walsh C; Lawson R; Reynolds A; Emery P
Article: ANNALS OF THE RHEUMATIC DISEASES. 2011;70(10):1726-1732
Autoantibodies as biomarkers for the prediction of neuropsychiatric events in systemic lupus erythematosus
Hanly JG; Urowitz MB; Su L; Bae S-C; Gordon C; Clarke A; Bernatsky S; Vasudevan A; Isenberg D; Rahman A; Wallace DJ; Fortin PR; Gladman D; Romero-Dirz J; Sanchez-Guerrero J; Dooley MA; Bruce I; Steinsson K; Khamashta M; Manzi S; Ramsey-Goldman R; Sturfelt G; Nived O; van Vollenhoven R; Ramos-Casals M; Aranow C; Mackay M; Kalunian K; Alarcon GS; Fessler BJ; Ruiz-Irastorza G; Petri M; Lim S; Kamen D; Peschken C; Farewell V; Thompson K; Theriault C; Merrill JT
Article: ANNALS OF THE RHEUMATIC DISEASES. 2011;70(9):1575-1580
Highest clinical effectiveness of rituximab in autoantibody-positive patients with rheumatoid arthritis and in those for whom no more than one previous TNF antagonist has failed: pooled data from 10 European registries
Chatzidionysiou K; Lie E; Nasonov E; Lukina G; Hetland ML; Tarp U; Gabay C; van Riel PLCM; Nordstrom DC; Gomez-Reino J; Pavelka K; Tomsic M; Kvien TK; van Vollenhoven RF
Article: ARTHRITIS & RHEUMATOLOGY. 2011;63(7):1782-1792
Atacicept in Patients With Rheumatoid Arthritis and an Inadequate Response to Methotrexate Results of a Phase II, Randomized, Placebo-Controlled Trial
van Vollenhoven RF; Kinnman N; Vincent E; Wax S; Bathon J
Article: ARTHRITIS CARE AND RESEARCH. 2011;63(7):1068-1072
Decreased Live Births in Women With Systemic Lupus Erythematosus
Vinet E; Clarke AE; Gordon C; Urowitz MB; Hanly JG; Pineau CA; Isenberg D; Rahman A; Wallace D; Alarcon GS; Bruce I; Petri M; Dooley MA; Kalunian K; Maddison P; Aranow C; van Vollenhoven R; Bernatsky S
Article: ANNALS OF THE RHEUMATIC DISEASES. 2011;70(6):996-1002
Certolizumab pegol plus methotrexate provides broad relief from the burden of rheumatoid arthritis: analysis of patient-reported outcomes from the RAPID 2 trial
Strand V; Smolen JS; van Vollenhoven RF; Mease P; Burmester GR; Hiepe F; Khanna D; Nikai E; Coteur G; Schiff M
Article: ANNALS OF THE RHEUMATIC DISEASES. 2011;70(6):1095-1098
Antibodies to citrullinated α-enolase peptide 1 and clinical and radiological outcomes in rheumatoid arthritis
Fisher BA; Plant D; Brode M; van Vollenhoven RF; Mathsson L; Symmons D; Lundberg K; Ronnelid J; Venables PJ
Article: ANNALS OF THE RHEUMATIC DISEASES. 2011;70(6):961-967
SF-36 summary and subscale scores are reliable outcomes of neuropsychiatric events in systemic lupus erythematosus
Hanly JG; Urowitz MB; Jackson D; Bae SC; Gordon C; Wallace DJ; Clarke A; Bernatsky S; Vasudevan A; Isenberg D; Rahman A; Sanchez-Guerrero J; Romero-Diaz J; Merrill JT; Fortin PR; Gladman DD; Bruce IN; Steinsson K; Khamashta M; Alarcon GS; Fessler B; Petri M; Manzi S; Nived O; Sturfelt G; Ramsey-Goldman R; Dooley MA; Aranow C; Van Vollenhoven R; Ramos-Casals M; Zoma A; Kalunian K; Farewell V
Article: ISRN RHEUMATOLOGY. 2011;2011:463124-5
Patient preference assessment reveals disease aspects not covered by recommended outcomes in polymyositis and dermatomyositis.
Alemo Munters L; van Vollenhoven RF; Alexanderson H
Article: LUPUS. 2011;20(3):250-255
Autoantibodies in systemic lupus erythematosus: comparison of historical and current assessment of seropositivity
Ippolito A; Wallace DJ; Gladman D; Fortin PR; Urowitz M; Werth V; Costner M; Gordon C; Alarcon GS; Ramsey-Goldman R; Maddison P; Clarke A; Bernatsky S; Manzi S; Bae S-C; Merrill JT; Ginzler E; Hanly JG; Nived O; Sturfelt G; Sanchez-Guerrero J; Bruce I; Aranow C; Isenberg D; Zoma A; Magder LS; Buyon J; Kalunian K; Dooley MA; Steinsson K; van Vollenhoven RF; Stoll T; Weisman M; Petri M
Article: ANNALS OF THE RHEUMATIC DISEASES. 2011;70(3):469-475
Predictors of response to methotrexate in early DMARD naive rheumatoid arthritis: results from the initial open-label phase of the SWEFOT trial
Saevarsdottir S; Wallin H; Seddighzadeh M; Ernestam SA; Geborek P; Petersson IF; Bratt J; van Vollenhoven RF
Article: ARTHRITIS RESEARCH & THERAPY. 2011;13(5):R141
Integrated safety in tocilizumab clinical trials
Schiff MH; Kremer JM; Jahreis A; Vernon E; Isaacs JD; van Vollenhoven RF
Article: RHEUMATOLOGY. 2011;50(1):204-213
Ten years with biologics: to whom do data on effectiveness and safety apply?
Simard JF; Arkema EV; Sundstrom A; Geborek P; Saxne T; Baecklund E; Coster L; Dackhammar C; Jacobsson L; Feltelius N; Lindblad S; Rantapaa-Dahlqvist S; Klareskog L; van Vollenhoven RF; Neovius M; Askling J
Article: ANNALS OF THE RHEUMATIC DISEASES. 2011;70(1):39-46
Inhibition of joint damage and improved clinical outcomes with rituximab plus methotrexate in early active rheumatoid arthritis: the IMAGE trial
Tak PP; Rigby WF; Rubbert-Roth A; Peterfy CG; van Vollenhoven RF; Stohl W; Hessey E; Chen A; Tyrrell H; Shaw TM
Article: ARTHRITIS CARE AND RESEARCH. 2011;63(1):128-134
American College of Rheumatology Hybrid Analysis of Certolizumab Pegol Plus Methotrexate in Patients With Active Rheumatoid Arthritis: Data From a 52-Week Phase III Trial
van Vollenhoven RF; Felson D; Strand V; Weinblatt ME; Luijtens K; Keystone EC
Article: RHEUMATOLOGY. 2010;49(11):2098-2103
Patient-reported 28 swollen and tender joint counts accurately represent RA disease activity and can be used to assess therapy responses at the group level
Riazzoli J; Nilsson J-A; Teleman A; Petersson IF; Rantapaa-Dahlqvist S; Jacobsson LTH; van Vollenhoven RF
Article: RHEUMATOLOGY. 2010;49(8):1502-1504
Clinical improvements in proliferative vs membranous lupus nephritis following B-cell depletion: pooled data from two cohorts
Jonsdottir T; Gunnarsson I; Mourao AF; Lu TY; van Vollenhoven RF; Isenberg D
Article: LUPUS. 2010;19(8):949-956
Disease activity and damage accrual during the early disease course in a multinational inception cohort of patients with systemic lupus erythematosus
Nossent J; Kiss E; Rozman B; Pokorny G; Vlachoyiannopoulos P; Olesinska M; Marchesoni A; Mosca M; Pai S; Manger K; Schneider M; Nielsen H; van Vollenhoven R; Swaak T
Article: ARTHRITIS CARE AND RESEARCH. 2010;62(6):881-887
Atherosclerotic Vascular Events in a Multinational Inception Cohort of Systemic Lupus Erythematosus
Urowitz MB; Gladman D; Ibanez D; Bae SC; Sanchez-Guerrero J; Gordon C; Clarke A; Bernatsky S; Fortin PR; Hanly JG; Wallace DJ; Isenberg D; Rahman A; Alarcon GS; Merrill JT; Ginzler E; Khamashta M; Nived O; Sturfelt G; Bruce IN; Steinsson K; Manzi S; Ramsey-Goldman R; Dooley MA; Zoma A; Kalunian K; Ramos M; Van Vollenhoven RF; Aranow C; Stoll T; Petri M; Maddison P
Article: DISCOVERY MEDICINE. 2010;9(47):319-327
New and Future Agents in the Treatment of Rheumatoid Arthritis
van Vollenhoven RF
Article: JOURNAL OF RHEUMATOLOGY. 2010;37(3):558-567
Longterm Safety of Patients Receiving Rituximab in Rheumatoid Arthritis Clinical Trials
van Vollenhoven RF; Emery P; Bingham COIII; Keystone EC; Fleischmann R; Furst DE; Macey K; Sweetser M; Kelman A; Rao R
Article: ANNALS OF THE RHEUMATIC DISEASES. 2010;69(3):529-535
Prospective analysis of neuropsychiatric events in an international disease inception cohort of patients with systemic lupus erythematosus
Hanly JG; Urowitz MB; Su L; Bae SC; Gordon C; Wallace DJ; Clarke A; Bernatsky S; Isenberg D; Rahman A; Alarcon GS; Gladman DD; Fortin PR; Sanchez-Guerrero J; Romero-Diaz J; Merrill JT; Ginzler E; Bruce IN; Steinsson K; Khamashta M; Petri M; Manzi S; Dooley MA; Ramsey-Goldman R; Van Vollenhoven R; Nived O; Sturfelt G; Aranow C; Kalunian K; Ramos-Casals M; Zoma A; Douglas J; Thompson K; Farewell V
Article: ARTHRITIS & RHEUMATOLOGY. 2010;62(2):351-358
The Selective Estrogen Receptor α Agonist Org 37663 Induces Estrogenic Effects but Lacks Antirheumatic Activity
van Vollenhoven RF; Houbiers JGA; Buttgereit F; in't Hout J; Boers M; Leij S; Kvien TK; Dijkmans BAC; Szczepanski L; Szombati I; Sierakowski S; Miltenburg AMM
Article: ANNALS OF THE RHEUMATIC DISEASES. 2010;69(2):394-399
Effectiveness of adalimumab in treating patients with active psoriatic arthritis and predictors of good clinical responses for arthritis, skin and nail lesions
Van den Bosch F; Manger B; Goupille P; McHugh N; Rodevand E; Holck P; van Vollenhoven RF; Leirisalo-Repo M; FitzGerald O; Kron M; Frank M; Kary S; Kupper H
Article: ARTHRITIS CARE AND RESEARCH. 2010;62(2):226-234
Improvement in Work Place and Household Productivity for Patients With Early Rheumatoid Arthritis Treated With Adalimumab Plus Methotrexate: Work Outcomes and Their Correlations With Clinical and Radiographic Measures From a Randomized Controlled Trial Companion Study
van Vollenhoven RF; Cifaldi MA; Ray S; Chen N; Weisman MH
Article: INTERNATIONAL JOURNAL OF TECHNOLOGY ASSESSMENT IN HEALTH CARE. 2010;26(1):54-61
Cost-effectiveness of real-world infliximab use in patients with rheumatoid arthritis in Sweden
Lekander I; Borgstrom F; Svarvar P; Ljung T; Carli C; van Vollenhoven RF
Article: ANNALS OF THE RHEUMATIC DISEASES. 2010;69(1):126-131
Patients with rheumatoid arthritis treated with tumour necrosis factor antagonists increase their participation in the workforce: potential for significant long-term indirect cost gains (data from a population-based registry)
Augustsson J; Neovius M; Cullinane-Carli C; Eksborg S; van Vollenhoven RF
Article: ARTHRITIS & RHEUMATOLOGY. 2009;61(11):1592-1600
Effect of Certolizumab Pegol With Methotrexate on Home and Work Place Productivity and Social Activities in Patients With Active Rheumatoid Arthritis
Kavanaugh A; Smolen JS; Emery P; Purcaru O; Keystone E; Richard L; Strand V; van Vollenhoven RF
Article: ARTHRITIS & RHEUMATOLOGY. 2009;60(11):3180-3189
Cancer Risk in Patients With Rheumatoid Arthritis Treated With Anti-Tumor Necrosis Factor α Therapies Does the Risk Change With the Time Since Start of Treatment?
Askling J; van Vollenhoven RF; Granath F; Raaschou P; Fored CM; Baecklund E; Dackhammar C; Feltelius N; Coster L; Geborek P; Jacobsson LT; Lindblad S; Rantapaa-Dahlqvist S; Saxne T; Klareskog L
Article: THE LANCET. 2009;374(9688):459-466
Addition of infliximab compared with addition of sulfasalazine and hydroxychloroquine to methotrexate in patients with early rheumatoid arthritis (Swefot trial): 1-year results of a randomised trial
van Vollenhoven RF; Ernestam S; Geborek P; Petersson IF; Coster L; Waltbrand E; Zickert A; Theander J; Thorner A; Hellstrom H; Teleman A; Dackhammar C; Akre F; Forslind K; Ljung L; Oding R; Chatzidionysiou A; Wornert M; Bratt J
Article: JOURNAL OF RHEUMATOLOGY. 2009;36(7):1429-1441
Less Radiographic Progression with Adalimumab Plus Methotrexate Versus Methotrexate Monotherapy Across the Spectrum of Clinical Response in Early Rheumatoid Arthritis
Emery P; Genovese MC; van Vollenhoven R; Sharp JT; Patra K; Sasso EH
Article: ANNALS OF THE RHEUMATIC DISEASES. 2009;68(6):797-804
Efficacy and safety of certolizumab pegol plus methotrexate in active rheumatoid arthritis: the RAPID 2 study. A randomised controlled trial
Smolen J; Landewe RB; Mease P; Brzezicki J; Mason D; Luijtens K; van Vollenhoven RF; Kavanaugh A; Schiff M; Burmester GR; Strand V; Vencovsky J; van der Heijde D
Article: ANNALS OF THE RHEUMATIC DISEASES. 2009;68(6):805-811
Efficacy and safety of certolizumab pegol monotherapy every 4 weeks in patients with rheumatoid arthritis failing previous disease-modifying antirheumatic therapy: the FAST4WARD study
Fleischmann R; Vencovsky J; van Vollenhoven RF; Borenstein D; Box J; Coteur G; Goel N; Brezinschek H-P; Innes A; Strand V
Article: ANNALS OF THE RHEUMATIC DISEASES. 2009;68(5):648-653
Anti-tumour necrosis factor therapy in rheumatoid arthritis and risk of malignant lymphomas: relative risks and time trends in the Swedish Biologics Register
Askling J; Baecklund E; Granath F; Geborek P; Fored M; Backlin C; Bertilsson L; Coster L; Jacobsson LT; Lindblad S; Lysholm J; Rantapaa-Dahlqvist S; Saxne T; van Vollenhoven R; Klareskog L; Feltelius N
Article: ANNALS OF THE RHEUMATIC DISEASES. 2009;68(4):456-459
Guidelines for initiation of anti-tumour necrosis factor therapy in rheumatoid arthritis: similarities and differences across Europe
Emery P; Van Vollenhoven R; Ostergaard M; Choy E; Combe B; Graninger W; Krueger K; Matucci-Cerinic M; Navarro F; van Riel P; Settas L; Steinfeld S
Article: ARTHRITIS RESEARCH & THERAPY. 2009;11(6):R170
Rapid and sustained improvements in health-related quality of life, fatigue, and other patient-reported outcomes in rheumatoid arthritis patients treated with certolizumab pegol plus methotrexate over 1 year: results from the RAPID 1 randomized controlled trial
Strand V; Mease P; Burmester GR; Nikai E; Coteur G; van Vollenhoven R; Combe B; Keystone EC; Kavanaugh A
Article: ARTHRITIS RESEARCH & THERAPY. 2009;11(3):R76
Blood autoantibody and cytokine profiles predict response to anti-tumor necrosis factor therapy in rheumatoid arthritis
Hueber W; Tomooka BH; Batliwalla F; Li W; Monach PA; Tibshirani RJ; Van Vollenhoven RF; Lampa J; Saito K; Tanaka Y; Genovese MC; Klareskog L; Gregersen PK; Robinson WH
Article: ANNALS OF THE RHEUMATIC DISEASES. 2008;67(11):1516-1523
IL-6 receptor inhibition with tocilizumab improves treatment outcomes in patients with rheumatoid arthritis refractory to anti-tumour necrosis factor biologicals: results from a 24-week multicentre randomised placebo-controlled trial
Emery P; Keystone E; Tony HP; Cantagrel A; van Vollenhoven R; Sanchez A; Alecock E; Lee J; Kremer J
Article: ARTHRITIS & RHEUMATOLOGY. 2008;58(11):3319-3329
Certolizumab Pegol Plus Methotrexate Is Significantly More Effective Than Placebo Plus Methotrexate in Active Rheumatoid Arthritis Findings of a Fifty-Two-Week, Phase III, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study
Keystone E; van der Heijde D; Mason DJ; Landewe R; van Vollenhoven R; Combe B; Emery P; Strand V; Mease P; Desai C; Pavelka K
Article: ARTHRITIS & RHEUMATOLOGY. 2008;59(10):1371-1377
Reporting Disease Activity in Clinical Trials of Patients With Rheumatoid Arthritis: EULAR/ACR Collaborative Recommendations
Aletaha D; Landewe R; Karonitsch T; Bathon J; Boers M; Bombardier C; Bombardieri S; Choi H; Combe B; Dougados M; Emery P; Gomez-Reino J; Keystone E; Koch G; Kvien TK; Martin-Mola E; Matucci-Cerinic M; Michaud K; O'Dell J; Paulus H; Pincus T; Richards P; Simon L; Siegel J; Smolen JS; Sokka T; Strand V; Tugwell P; van der Heijde D; van Riel P; Vlad S; van Vollenhoven R; Ward M; Weinblatt M; Wells G; White B; Wolfe F; Zhang B; Zink A; Felson D
Article: ANNALS OF THE RHEUMATIC DISEASES. 2008;67(10):1360-1364
Reporting disease activity in clinical trials of patients with rheumatoid arthritis: EULAR/ACR collaborative recommendations
Aletaha D; Landewe R; Karonitsch T; Bathon J; Boers M; Bombardier C; Bombardieri S; Choi H; Combe B; Dougados M; Emery P; Gomez-Reino J; Keystone E; Koch G; Kvien TK; Martin-Mola E; Matucci-Cerinic M; Michaud K; O'Dell J; Paulus H; Pincus T; Richards P; Simon L; Siegel J; Smolen JS; Sokka T; Strand V; Tugwell P; van der Heijde D; van Riel P; Vlad S; van Vollenhoven R; Ward M; Weinblatt M; Wells G; White B; Wolfe F; Zhang B; Zink A; Felson D
Article: ANNALS OF THE RHEUMATIC DISEASES. 2008;67(9):1267-1270
Level of radiographic damage and radiographic progression are determinants of physical function: a longitudinal analysis of the TEMPO trial
van der Heijde D; Landewe R; van Vollenhoven R; Fatenejad S; Klareskog L
Article: ARTHRITIS & RHEUMATOLOGY. 2008;58(6):1784-1788
Systemic lupus international collaborating clinics renal activity/response exercise - Development of a renal activity score and renal response index
Petri M; Kasitanon N; Lee S-S; Link K; Magder L; Bae S-C; Hanly JG; Isenberg DA; Nived O; Sturfelt G; van Vollenhoven R; Wallace DJ; Alarcon GS; Adu D; Avila-Casado C; Bernatsky SR; Bruce IN; Clarke AE; Contreras G; Fine DM; Gladman DD; Gordon C; Kalunian KC; Madaio MP; Rovin BH; Sanchez-Guerrero J; Steinsson K; Aranow C; Balow JE; Buyon JP; Ginzler EM; Khamashta MA; Urowitz MB; Dooley MA; Merrill JT; Ramsey-Goldman R; Font J; Tumlin J; Stoll T; Zoma A
Article: ARTHRITIS & RHEUMATOLOGY. 2008;58(6):1789-1795
Systemic lupus international collaborating clinics renal activity/response exercise -: Comparison of agreement in rating renal response
Petri M; Kasitanon N; Singh S; Link K; Magder L; Bae S-C; Hanly JG; Nived O; Sturfelt G; van Vollenhoven R; Wallace DJ; Alarcon GS; Adu D; Avila-Casado C; Bernatsky SR; Bruce IN; Clarke AE; Contreras G; Fine DM; Gladman DD; Gordon C; Kalunian KC; Madaio MP; Rovin BH; Sanchez-Guerrero J; Steinsson K; Aranow C; Balow JE; Buyon JP; Ginzler EM; Khamashta MA; Urowitz MB; Dooley MA; Merrill JT; Ramsey-Goldman R; Font J; Tumlin J; Stoll T; Zoma A
Article: ARTHRITIS & RHEUMATOLOGY. 2008;59(5):721-729
Short-term outcome of neuropsychiatric events in systemic lupus erythematosus upon enrollment into an international inception cohort study
Hanly JG; Urowitz MB; Su L; Sanchez-Guerrero J; Bae SC; Gordon C; Wallace DJ; Isenberg D; Alarcon GS; Merrill JT; Clarke A; Bernatsky S; Dooley MA; Fortin PR; Gladman D; Steinsson K; Petri M; Bruce IN; Manzi S; Khamashta M; Zoma A; Font J; Van Vollenhoven R; Aranow C; Ginzler E; Nived O; Sturfelt G; Ramsey-Goldman R; Kalunian K; Douglas J; Qi KQ; Thompson K; Farewell V
Article: ANNALS OF THE RHEUMATIC DISEASES. 2008;67(3):330-334
Treatment of refractory SLE with rituximab plus cyclophosphamide:: clinical effects, serological changes, and predictors of response
Jonsdottir T; Gunnarsson I; Risselada A; Henriksson EW; Klareskog L; van Vollenhoven RF
Article: ARTHRITIS & RHEUMATOLOGY. 2008;58(3):843-853
Autoantibodies and neuropsychiatric events at the time of systemic lupus erythematosus diagnosis
Hanly JG; Urowitz MB; Siannis F; Farewell V; Gordon C; Bae SC; Isenberg D; Dooley MA; Clarke A; Bernatsky S; Gladman D; Fortin PR; Manzi S; Steinsson K; Bruce IN; Ginzler E; Aranow C; Wallace DJ; Ramsey-Goldman R; van Vollenhoven R; Sturfelt G; Nived O; Sanchez-Guerrero J; Alarcon GS; Petri M; Khamashta M; Zoma A; Font J; Kalunian K; Douglas J; Qi Q; Thompson K; Merrill JT
Article: ARTHRITIS & RHEUMATOLOGY. 2008;59(2):176-180
Accumulation of coronary artery disease risk factors over three years: data from an international inception cohort.
Urowitz MB; Gladman D; Ibañez D; Fortin P; Sanchez-Guerrero J; Bae S; Clarke A; Bernatsky S; Gordon C; Hanly J; Wallace D; Isenberg D; Ginzler E; Merrill J; Alarcón GS; Steinsson K; Petri M; Dooley MA; Bruce I; Manzi S; Khamashta M; Ramsey-Goldman R; Zoma A; Sturfelt G; Nived O; Maddison P; Font J; van Vollenhoven R; Aranow C; Kalunian K; Stoll T; Systemic Lupus International Collaborating Clinics
Article: ARTHRITIS & RHEUMATOLOGY. 2008;58(1):36-45
Antibodies against citrullinated vimentin in rheumatoid arthritis
Mathsson L; Mullazehi M; Wick MC; Sjoberg O; van Vollenhoven R; Klareskog L; Ronnelid J
Article: ARTHRITIS & RHEUMATOLOGY. 2007;56(12):3896-3908
Safety and efficacy of additional courses of rituximab in patients with active rheumatoid arthritis
Keystone E; Fleischmann R; Emery P; Furst DE; van Vollenhoven R; Bathon J; Dougados M; Baldassare A; Ferraccioli G; Chubick A; Udell J; Cravets MW; Agarwal S; Cooper S; Magrini F
Article: SCANDINAVIAN JOURNAL OF RHEUMATOLOGY. 2007;36(6):418-423
Infliximab dosage and infusion frequency in clinical practice: experiences in the Stockholm biologics registry STURE
van Vollenhoven RF; Klareskog L
Article: ANNALS OF THE RHEUMATIC DISEASES. 2007;66(11):1462-1466
Low-dose glucocorticoid therapy decreases risk for treatment-limiting infusion reaction to infliximab in patients with rheumatoid arthritis
Augustsson J; Eksborg S; Ernestam S; Gullstrom E; van Vollenhoven R
Article: ANNALS OF THE RHEUMATIC DISEASES. 2007;66(10):1339-1344
Time-dependent increase in risk of hospitalisation with infection among Swedish RA patients treated with TNF antagonists
Askling J; Fored CM; Brandt L; Baecklund E; Bertilsson L; Feltelius N; Coster L; Geborek P; Jacobsson LT; Lindblad S; Lysholm J; Rantapaa-Dahlqvist S; Saxne T; van Vollenhoven RF; Klareskog L
Article: ARTHRITIS & RHEUMATOLOGY. 2007;56(4):1263-1272
Histopathologic and clinical outcome of rituximab treatment in patients with cyclophosphamide-resistant proliferative lupus nephritis
Gunnarsson I; Sundelin B; Jonsdottir T; Jacobson SH; Henriksson EW; van Vollenhoven RF
Article: LUPUS. 2007;16(9):731-735
Clinical manifestations and coronary artery disease risk factors at diagnosis of systemic lupus erythematosus: data from an international inception cohort.
Urowitz MB; Gladman D; Ibañez D; Fortin P; Sanchez-Guerrero J; Bae S; Clarke A; Bernatsky S; Gordon C; Hanly J; Wallace D; Isenberg D; Ginzler E; Merrill J; Alarcon G; Steinsson K; Petri M; Dooley MA; Bruce I; Manzi S; Khamashta M; Ramsey-Goldman R; Zoma A; Sturfelt G; Nived O; Maddison P; Font J; van Vollenhoven R; Aranow C; Kalunian K; Stoll T; Buyon J
Article: CLINICAL IMMUNOLOGY. 2007;122(1):62-74
Treatment with rituximab affects both the cellular and the humoral arm of the immune system in patients with SLE
Vallerskog T; Gunnarsson I; Widhe M; Risselada A; Klareskog L; van Vollenhoven R; Malmstrom V; Trollmo C
Article: ARTHRITIS & RHEUMATOLOGY. 2007;56(1):265-273
Neuropsychiatric events at the time of diagnosis of systemic lupus erythematosus -: An international inception cohort study
Hanly JG; Urowitz MB; Sanchez-Guerrero J; Bae SC; Gordon C; Wallace DJ; Isenberg D; Alarcon GS; Clarke A; Bernatsky S; Merrill JT; Petri M; Dooley MA; Gladman D; Fortin PR; Steinsson K; Bruce I; Manzi S; Khamashta M; Zoma A; Aranow C; Ginzler E; Van Vollenhoven R; Font J; Sturfelt G; Nived O; Ramsey-Goldman R; Kalunian K; Douglas J; Thompson K; Farewell V
Article: ARTHRITIS RESEARCH & THERAPY. 2007;9(5):R87
Skewed distribution of proinflammatory CD4⁺CD28^null T cells in rheumatoid arthritis
Fasth AE; Snir O; Johansson AA; Nordmark B; Rahbar A; af Klint E; Bjorkstrom NK; Ulfgren A-K; van Vollenhoven RF; Malmstrom V; Trollmo C
Article: ARTHRITIS & RHEUMATOLOGY. 2006;54(10):3119-3125
Disconnect between inflammation and joint destruction after treatment with etanercept plus methotrexate -: Results from the trial of etanercept and methotrexate with radiographic and patient outcomes
Landewe R; van der Heijde D; Klareskog L; van Vollenhoven R; Fatenejad S
Article: ARTHRITIS & RHEUMATOLOGY. 2006;54(5):1390-1400
The efficacy and safety of rituximab in patients with active rheumatoid arthritis despite methotrexate treatment - Results of a phase IIb randomized, double-blind, placebo-controlled, dose-ranging trial
Emery P; Fleischmann R; Filipowicz-Sosnowska A; Schechtman J; Szczepanski L; Kavanaugh A; Racewicz AJ; Van Vollenhoven RF; Li NF; Agarwal S; Hessey EW; Shaw TM
Article: ARTHRITIS & RHEUMATOLOGY. 2006;54(1):26-37
The PREMIER study - A multicenter, randomized, double-blind clinical trial of combination therapy with adalimumab plus methotrexate versus methotrexate alone or adalimumab alone in patients with early, aggressive rheumatoid arthritis who had not had previous methotrexate treatment
Breedveld FC; Weisman MH; Kavanaugh AF; Cohen SB; Pavelka K; van Vollenhoven R; Sharp J; Perez JL; Spencer-Green GT
Article: SCANDINAVIAN JOURNAL OF RHEUMATOLOGY. 2005;34(5):353-358
Adalimumab (Humira®) restores clinical response in patients with secondary loss of efficacy from infliximab (Remicade®) or etanercept (Enbrel®):: results from the STURE registry at Karolinska University Hospital
Wick MC; Ernestam S; Lindblad S; Bratt J; Klareskog L; van Vollenhoven RF
Article: ANNALS OF THE RHEUMATIC DISEASES. 2005;64(12):1744-1749
Longitudinal analysis of citrullinated protein/peptide antibodies (anti-CP) during 5 year follow up in early rheumatoid arthritis:: anti-CP status predicts worse disease activity and greater radiological progression
Rönnelid J; Wick MC; Lampa J; Lindblad S; Nordmark B; Klareskog L; van Vollenhoven RF
Article: CLINICAL AND EXPERIMENTAL RHEUMATOLOGY. 2005;23(5):S195-S200
Rheumatoid arthritis registries in Sweden
van Vollenhoven RF; Askling J
Article: ANNALS OF THE RHEUMATIC DISEASES. 2005;64(4):654
Feasibility of 1 hour infliximab infusions
van Vollenhoven RF; Gullström E; Klareskog L
Article: ANNALS OF THE RHEUMATIC DISEASES. 2005;64(1):134-137
Estimated prediagnosis radiological progression: an important tool for studying the effects of early disease modifying antirheumatic drug treatment in rheumatoid arthritis
Wick MC; Lindblad S; Weiss RJ; Klareskog L; van Vollenhoven RF
Article: SCANDINAVIAN JOURNAL OF RHEUMATOLOGY. 2004;33(6):423-427
Biopsy-verified response of severe lupus nephritis to treatment with rituximab (anti-CD20 monoclonal antibody) plus cyclophosphamide after biopsy-documented failure to respond to cyclophosphamide alone
van Vollenhoven RF; Gunnarsson I; Welin-Henriksson E; Sundelin B; Österborg A; Jacobson SH; Klareskog L
Article: SCANDINAVIAN JOURNAL OF RHEUMATOLOGY. 2004;33(6):380-384
Clinical and radiological disease-course in a Swedish DMARD-treated early RA-inception cohort: an observational study
Wick MC; Lindblad S; Weiss RJ; Klareskog L; van Vollenhoven RF
Article: CLINICAL AND EXPERIMENTAL RHEUMATOLOGY. 2004;22(5):S122-S125
Benefits and risks of biological agents: Lymphomas
van Vollenhoven RF
Article: CLINICAL AND EXPERIMENTAL RHEUMATOLOGY. 2004;22(5):S115-S121
Switching between biological agents
van Vollenhoven RF
Article: ANNALS OF THE RHEUMATIC DISEASES. 2004;63(9):1075-1078
Treatment with tumour necrosis factor a antagonists in patients with rheumatoid arthritis induces anticardiolipin antibodies
Jonsdottir T; Forslid J; van Vollenhoven A; Harju A; Brannemark S; Klareskog L; van Vollenhoven RF
Article: ANNALS OF THE RHEUMATIC DISEASES. 2004;63(7):848-852
Relationship between inflammation and joint destruction in early rheumatoid arthritis: a mathematical description
Wick MC; Lindblad S; Klareskog L; van Vollenhoven RF
Article: SCANDINAVIAN JOURNAL OF IMMUNOLOGY. 2004;60(1-2):199-208
CD28^nullCD4⁺ T cells -: Characterization of an effector memory T-cell population in patients with rheumatoid arthritis
Fasth AER; Cao D; van Vollenhoven R; Trollmo C; Malmström V
Article: ANNALS OF THE RHEUMATIC DISEASES. 2004;63(4):426-430
Dose escalation of infliximab in clinical practice: improvements seen may be explained by a regression-like effect
van Vollenhoven RF; Brannemark S; Klareskog L
Article: ARTHRITIS RESEARCH & THERAPY. 2004;6(4):R335-R346
CD25^brightCD4⁺ regulatory T cells are enriched in inflamed joints of patients with chronic rheumatic disease
Cao DJ; van Vollenhoven R; Klareskog L; Trollmo C; Malmström V
Article: ANNALS OF THE RHEUMATIC DISEASES. 2003;62(12):1195-1198
Treatment with infliximab (Remicade) when etanercept (Enbrel) has failed or vice versa:: data from the STURE registry showing that switching tumour necrosis factor α blockers can make sense
van Vollenhoven R; Harju A; Brannemark S; Klareskog L
Article: ARTHRITIS & RHEUMATOLOGY. 2003;48(6):1500-1503
Clinical responses to tumor necrosis factor α antagonists do not show a bimodal distribution -: Data from the Stockholm tumor necrosis factor α followup registry
van Vollenhoven RF; Klareskog L
Article: JOURNAL OF RHEUMATOLOGY. 2003;30(3):449-454
Allele and antigen-specific treatment of rheumatoid arthritis: A double blind, placebo controlled phase 1 trial
Kavanaugh A; Genovese M; Baughman J; Kivitz A; Bulpitt K; Olsen N; Weisman M; Matteson E; Furst D; van Vollenhoven R; Anderson J; Cohen S; Wei N; Meijerink J; Jacobs C; Mocci S
Article: ARTHRITIS RESEARCH & THERAPY. 2003;5(6):R347-R351
Etanercept versus etanercept plus methotrexate: a registry-based study suggesting that the combination is clinically more efficacious
van Vollenhoven RF; Ernestam S; Harju A; Bratt J; Klareskog L
Article: JOURNAL OF RHEUMATOLOGY. 2002;29(10):2114-2121
VH4-34 encoded antibody in systemic lupus erythematosus: Effect of Isotype
Bhat NM; Lee LM; van Vollenhoven RF; Teng NNH; Bieber MM
Article: JOURNAL OF RHEUMATOLOGY. 2002;29(4):693-699
Repeated renal biopsy in proliferative lupus nephritis -: Predictive role of serum C1q and albuminuria
Gunnarsson I; Sundelin B; Heimbürger M; Forslid J; van Vollenhoven R; Lundberg I; Jacobson SH
Article: ANNALS OF THE RHEUMATIC DISEASES. 2001;60(4):372-379
Increased levels of proinflammatory cytokines and nitric oxide metabolites in neuropsychiatric lupus erythematosus
Svenungsson E; Andersson M; Brundin L; van Vollenhoven R; Khademi M; Tarkowski A; Greitz D; Dahlström M; Lundberg I; Klareskog L; Olsson T
Article: ANNALS OF THE RHEUMATIC DISEASES. 2001;60(2):133-139
Increased peripheral T cell reactivity to microbial antigens and collagen type II in rheumatoid arthritis after treatment with soluble TNFα receptors
Berg L; Lampa J; Rogberg S; van Vollenhoven R; Klareskog L
Article: RHEUMATIC DISEASE CLINICS OF NORTH AMERICA. 2000;26(2):349-362
Dehydroepiandrosterone in systemic lupus erythematosus.
van Vollenhoven RF
Article: JOURNAL OF RHEUMATOLOGY. 1999;26(10):2153-2158
Psychosocial correlates of morbidity in women with systemic lupus erythematosus.
Ward MM; Lotstein DS; Bush TM; Lambert RE; van Vollenhoven R; Neuwelt CM
Article: JOURNAL OF RHEUMATOLOGY. 1999;26(8):1727-1733
VH4-34 encoded antibodies in systemic lupus erythematosus: A specific diagnostic marker that correlates with clinical disease characteristics
van Vollenhoven RF; Bieber MM; Powell MJ; Gupta PK; Bhat NM; Richards KL; Albano SA; Teng NNH
Article: JOURNAL OF CLINICAL RHEUMATOLOGY. 1999;5(4):228-232
Treatment of severe CNS lupus with intravenous immunoglobulin.
Engel G; van Vollenhoven RF
Article: JOURNAL OF CLINICAL RHEUMATOLOGY. 1999;5(1):9-16
Influence of hormonal events on disease expression in patients with the combination of systemic lupus erythematosus and rheumatoid arthritis.
Sundaramurthy SG; Karsevar MP; van Vollenhoven RF
Article: JOURNAL OF RHEUMATOLOGY. 1999;26(1):197
Severe rheumatoid arthritis.
van Vollenhoven RF
Article: LUPUS. 1999;8(3):181-187
A double-blind, placebo-controlled, clinical trial of dehydroepiandrosterone in severe systemic lupus erythematosus
van Vollenhoven RF; Park JL; Genovese MC; West JP; McGuire JL
Article: JOURNAL OF RHEUMATOLOGY. 1998;25(12):2352-2356
Dehydroepiandrosterone in systemic lupus erythematosus: relationship between dosage, serum levels, and clinical response.
Barry NN; McGuire JL; van Vollenhoven RF
Article: JOURNAL OF RHEUMATOLOGY. 1998;25(9):1720-1729
Socioeconomic status and health in women with systemic lupus erythematosus.
Lotstein DS; Ward MM; Bush TM; Lambert RE; van Vollenhoven R; Neuwelt CM
Article: JOURNAL OF RHEUMATOLOGY. 1998;25(2):285-289
Treatment of systemic lupus erythematosus with dehydroepiandrosterone: 50 patients treated up to 12 months.
van Vollenhoven RF; Morabito LM; Engleman EG; McGuire JL
Article: POSTGRADUATE MEDICINE. 1998;103(2):137-142
Corticosteroids in rheumatic disease. Understanding their effects is key to their use.
van Vollenhoven RF
Article: POSTGRADUATE MEDICINE. 1998;103(2):103-123
Rheumatoid arthritis. Designing and implementing a treatment plan.
Gremillion RB; van Vollenhoven RF
Article: AMERICAN JOURNAL OF MEDICINE. 1997;103(3):233-241
Skeletal status of men with early and late ankylosing spondylitis.
Lee YS; Schlotzhauer T; Ott SM; van Vollenhoven RF; Hunter J; Shapiro J; Marcus R; McGuire JL
Article: ANNALES DE MEDECINE INTERNE. 1996;147(4):290-296
Studies of dehydroepiandrosterone (DHEA) as a therapeutic agent in systemic lupus erythematosus.
Van Vollenhoven RF; McGuire JL
Article: ARTHRITIS & RHEUMATOLOGY. 1995;38(12):1826-1831
Dehydroepiandrosterone in systemic lupus erythematosus. Results of a double-blind, placebo-controlled, randomized clinical trial.
van Vollenhoven RF; Engleman EG; McGuire JL
Visa fler

Alla övriga publikationer

Review: ANNALS OF THE RHEUMATIC DISEASES. 2020;79(6):685-699
EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2019 update
Smolen JS; Landewe RBM; Bijlsma JWJ; Burmester GR; Dougados M; Kerschbaumer A; McInnes IB; Sepriano A; van Vollenhoven RF; de Wit M; Aletaha D; Aringer M; Askling J; Balsa A; Boers M; den Broeder AA; Buch MH; Buttgereit F; Caporali R; Cardiel MH; De Cock D; Codreanu C; Cutolo M; Edwards CJ; van Eijk-Hustings Y; Emery P; Finckh A; Gossec L; Gottenberg J-E; Hetland ML; Huizinga TWJ; Koloumas M; Li Z; Mariette X; Mueller-Ladner U; Mysler EF; da Silva JAP; Poor G; Pope JE; Rubbert-Roth A; Ruyssen-Witrand A; Saag KG; Strangfeld A; Takeuchi T; Voshaar M; Westhovens R; van der Heijde D
Review: ANNALS OF THE RHEUMATIC DISEASES. 2020;79(6):713-723
2019 Update of the Joint European League Against Rheumatism and European Renal Association-European Dialysis and Transplant Association (EULAR/ERA-EDTA) recommendations for the management of lupus nephritis
Fanouriakis A; Kostopoulou M; Cheema K; Anders H-J; Aringer M; Bajema I; Boletis J; Frangou E; Houssiau FA; Hollis J; Karras A; Marchiori F; Marks SD; Moroni G; Mosca M; Parodis I; Praga M; Schneider M; Smolen JS; Tesar V; Trachana M; van Vollenhoven RF; Voskuyl AE; Teng YKO; van Leew B; Bertsias G; Jayne D; Boumpas DT
Review: ANNALS OF THE RHEUMATIC DISEASES. 2019;78(9):1160-1166
2018 EULAR recommendations for a core data set to support observational research and clinical care in giant cell arteritis
Ehlers L; Askling J; Bijlsma HWJ; Cid MC; Cutolo M; Dasgupta B; Dejaco C; Dixon WG; Feltelius N; Finckh A; Gilbert K; Mackie SL; Mahr A; Matteson EL; Neill L; Salvarani C; Schmidt WA; Strangfeld A; van Vollenhoven RF; Buttgereit F
Letter: ANNALS OF THE RHEUMATIC DISEASES. 2019;78(7):1010-1012
Low aspirin use and high prevalence of pre-eclampsia risk factors among pregnant women in a multinational SLE inception cohort
Mendel A; Bernatsky SB; Hanly JG; Urowitz MB; Clarke AE; Romero-Diaz J; Gordon C; Bae S-C; Wallace DJ; Merrill JT; Buyon JP; Isenberg DA; Rahman A; Ginzler EM; Petri M; Dooley MA; Fortin PR; Gladman DD; Steinsson K; Ramsey-Goldman R; Khamashta MA; Aranow C; Mackay M; Alarcon GS; Manzi S; Nived O; Jonsen A; Zoma AA; van Vollenhoven RF; Ramos-Casals M; Ruiz-Irastorza G; Lim S; Kalunian KC; Inanc M; Kamen DL; Peschken CA; Jacobsen S; Askanase A; Sanchez-Guerrero J; Bruce IN; Costedoat-Chalumeau N; Vinet E
Review: ANNALS OF THE RHEUMATIC DISEASES. 2019;78(6):736-745
2019 update of the EULAR recommendations for the management of systemic lupus erythematosus
Fanouriakis A; Kostopoulou M; Alunno A; Aringer M; Bajema I; Boletis JN; Cervera R; Doria A; Gordon C; Govoni M; Houssiau F; Jayne D; Kouloumas M; Kuhn A; Larsen JL; Lerstrom K; Moroni G; Mosca M; Schneider M; Smolen JS; Svenungsson E; Tesar V; Tincani A; Troldborg A; van Vollenhoven R; Wenzel J; Bertsias G; Boumpas DT
Review: NATURE REVIEWS. RHEUMATOLOGY. 2018;14(2):75-93
Moving towards a molecular taxonomy of autoimmune rheumatic diseases
Barturen G; Beretta L; Cervera R; Van Vollenhoven R; Alarcon-Riquelme ME
Review: ANNALS OF THE RHEUMATIC DISEASES. 2017;76(6):960-977
EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2016 update
Smolen JS; Landewe R; Bijlsma J; Burmester G; Chatzidionysiou K; Dougados M; Nam J; Ramiro S; Voshaar M; van Vollenhoven R; Aletaha D; Aringer M; Boers M; Buckley CD; Buttgereit F; Bykerk V; Cardiel M; Combe B; Cutolo M; van Eijk-Hustings Y; Emery P; Finckh A; Gabay C; Gomez-Reino J; Gossec L; Gottenberg J-E; Hazes JMW; Huizinga T; Jani M; Karateev D; Kouloumas M; Kvien T; Li Z; Mariette X; McInnes I; Mysler E; Nash P; Pavelka K; Poor G; Richez C; van Riel P; Rubbert-Roth A; Saag K; da Silva J; Stamm T; Takeuchi T; Westhovens R; de Wit M; van der Heijde D
Review: ANNALS OF THE RHEUMATIC DISEASES. 2017;76(6):1102-1107
Efficacy of glucocorticoids, conventional and targeted synthetic disease-modifying antirheumatic drugs: a systematic literature review informing the 2016 update of The EULAR recommendations for the management of rheumatoid arthritis
Chatzidionysiou K; Emamikia S; Nam J; Ramiro S; Smolen J; van der Heijde D; Dougados M; Bijlsma J; Burmester G; Scholte M; van Vollenhoven R; Landewe R
Review: ANNALS OF THE RHEUMATIC DISEASES. 2017;76(6):1101-1136
Safety of synthetic and biological DMARDs: a systematic literature review informing the 2016 update of the EULAR recommendations for management of rheumatoid arthritis
Ramiro S; Sepriano A; Chatzidionysiou K; Nam JL; Smolen JS; van der Heijde D; Dougados M; van Vollenhoven R; Bijlsma JW; Burmester GR; Scholte-Voshaar M; Falzon L; Landewe RBM
Review: ANNALS OF THE RHEUMATIC DISEASES. 2017;76(6):1113-1136
Efficacy of biological disease-modifying antirheumatic drugs: a systematic literature review informing the 2016 update of the EULAR recommendations for the management of rheumatoid arthritis
Nam JL; Takase-Minegishi K; Ramiro S; Chatzidionysiou K; Smolen JS; van der Heijde D; Bijlsma JW; Burmester GR; Dougados M; Scholte-Voshaar M; van Vollenhoven R; Landewe R
Review: ANNALS OF THE RHEUMATIC DISEASES. 2017;76(6):948-959
2016 update of the EULAR recommendations for the management of early arthritis
Combe B; Landewe R; Daien CI; Hua C; Aletaha D; Alvaro-Gracia JM; Bakkers M; Brodin N; Burmester GR; Codreanu C; Conway R; Dougados M; Emery P; Ferraccioli G; Fonseca J; Raza K; Silva-Fernandez L; Smolen JS; Skingle D; Szekanecz Z; Kvien TK; van der Helm-van Mil A; van Vollenhoven R
Letter: ANNALS OF THE RHEUMATIC DISEASES. 2016;75(10):e69
Response to: "Let's stop fooling ourselves. In RA, only ACR/EULAR criteria define remission and equate with absence of disease!' by Boers
Emery P; Bingham COIII; Burmester GR; Bykerk VP; Furst DE; Mariette X; van der Heijde D; van Vollenhoven R; Arendt C; Mountian I; Purcaru O; Tatla D; VanLunen B; Weinblatt ME
Letter: ARTHRITIS CARE AND RESEARCH. 2016;68(7):1051
Choosing Wisely in daily practice: an intervention study on antinuclear antibody testing by rheumatologists. Comment on the article by Lesuis et al Reply
Lesuis N; Piek E; Demirel H; den Broeder AA; Hulscher MEJL; Meek I; van der Laan-Baalbergen N; van Vollenhoven RF
Letter: ARTHRITIS CARE AND RESEARCH. 2016;68(7):1053-1054
Hydroxychloroquine in systemic lupus erythematosus: comment on the article by Muangchan et al Reply
Pope JE; Rothfield NF; Ramsey-Goldman R; Smith CD; Bernatsky SR; Furie RA; Hudson M; Burgos-Vargas R; Senecal J-L; Inanc M; van Vollenhoven RF; Chandran V; Nash PT; Muangchan C
Corrigendum: ARTHRITIS RESEARCH & THERAPY. 2016;18(1):144
Effectiveness of two different doses of rituximab for the treatment of rheumatoid arthritis in an international cohort: data from the CERERRA collaboration (vol 18, 50, 2016)
Chatzidionysiou K; Lie E; Nasonov E; Lukina G; Hetland ML; Tarp U; Ancuta I; Pavelka K; Nordstrom DC; Gabay C; Canhao H; Tomsic M; van Riel PLCM; Gomez-Reino J; Kvien TK; van Vollenhoven RF
Editorial comment: CLINICAL EPIDEMIOLOGY. 2016;8:361-362
Prevalence and comorbidity of relapsing polychondritis
Ludvigsson JF; van Vollenhoven R
Review: ANNALS OF THE RHEUMATIC DISEASES. 2016;75(1):16-22
Evidence for treating rheumatoid arthritis to target: results of a systematic literature search update
Stoffer MA; Schoels MM; Smolen JS; Aletaha D; Breedveld FC; Burmester G; Bykerk V; Dougados M; Emery P; Haraoui B; Gomez-Reino J; Kvien TK; Nash P; Navarro-Compan V; Scholte-Voshaar M; van Vollenhoven R; van der Heijde D; Stamm TA
Review: ANNALS OF THE RHEUMATIC DISEASES. 2016;75(1):3-15
Treating rheumatoid arthritis to target: 2014 update of the recommendations of an international task force
Smolen JS; Breedveld FC; Burmester GR; Bykerk V; Dougados M; Emery P; Kvien TK; Navarro-Compan MV; Oliver S; Schoels M; Scholte-Voshaar M; Stamm T; Stoffer M; Takeuchi T; Aletaha D; Louis Andreu J; Aringer M; Bergman M; Betteridge N; Bijlsma H; Burkhardt H; Cardiel M; Combe B; Durez P; Fonseca JE; Gibofsky A; Gomez-Reino JJ; Graninger W; Hannonen P; Haraoui B; Kouloumas M; Landewe R; Martin-Mola E; Nash P; Ostergaard M; Ostor A; Richards P; Sokka-Isler T; Thorne C; Tzioufas AG; van Vollenhoven R; de Wit M; van der Heijde D
Editorial comment: ANNALS OF THE RHEUMATIC DISEASES. 2015;74(12):2103-2106
Remission in SLE: closing in on the target
van Vollenhoven RF; Voskuyl A; Morand E; Aranow C
Letter: ANNALS OF THE RHEUMATIC DISEASES. 2015;74(12):2260-2261
Adalimumab and etanercept serum (anti)drug levels are not predictive for successful dose reduction or discontinuation in rheumatoid arthritis
van Herwaarden N; Bouman CAM; van der Maas A; van Vollenhoven RF; Bijlsma JW; van den Hoogen FHJ; den Broeder AA; van den Bemt BJF
Review: ARTHRITIS RESEARCH & THERAPY. 2015;17(1):181
Sustained biologic-free and drug-free remission in rheumatoid arthritis, where are we now?
Nagy G; van Vollenhoven RF
Letter: LUPUS. 2015;24(6):648-649
DRESS syndrome and reversible liver function abnormalities in patients with systemic lupus erythematosus treated with the highly selective JAK-1 inhibitor GSK2586184
van Vollenhoven RF; Layton M; Kahl L; Schifano L; Hachulla E; Machado D; Staumont-Salle D; Patel J
Letter: ANNALS OF THE RHEUMATIC DISEASES. 2014;73(11):e73
Response to: 'MBDA: what is it good for?' by Yazici et al
van Vollenhoven R; Hambardzumyan K; Chernoff D; Bolce R
Review: COCHRANE DATABASE OF SYSTEMATIC REVIEWS. 2014;(9):CD010455
Down-titration and discontinuation strategies of tumor necrosis factor-blocking agents for rheumatoid arthritis in patients with low disease activity
van Herwaarden N; den Broeder AA; Jacobs W; van der Maas A; Bijlsma JWJ; van Vollenhoven RF; van den Bemt BHJF
Review: ANNALS OF THE RHEUMATIC DISEASES. 2014;73(6):958-967
Treat-to-target in systemic lupus erythematosus: recommendations from an international task force
van Vollenhoven RF; Mosca M; Bertsias G; Isenberg D; Kuhn A; Lerstrom K; Aringer M; Bootsma H; Boumpas D; Bruce IN; Cervera R; Clarke A; Costedoat-Chalumeau N; Czirjak L; Derksen R; Doerner T; Gordon C; Graninger W; Houssiau F; Inanc M; Jacobsen S; Jayne D; Jedryka-Goral A; Levitsky A; Levy R; Mariette X; Morand E; Navarra S; Neumann I; Rahman A; Rovensky J; Smolen J; Vasconcelos C; Voskuyl A; Voss A; Zakharova H; Zoma A; Schneider M
Editorial comment: BMC MEDICINE. 2014;12:25
Early start and stop of biologics: has the time come?
van Vollenhoven RF; Nagy G; Tak PP
Letter: ARTHRITIS & RHEUMATOLOGY. 2014;66(2):480
Relevance of different results of different anti-double-stranded DNA assays in reporting clinical studies: comment on the article by Petri et al Reply
Petri MA; van Vollenhoven RF; Buyon J; Levy RA; Navarra SV; Cervera R; Zhong ZJ; Freimuth WW
Review: F1000 PRIME REPORTS. 2014;6:31
Advances in the treatment of rheumatoid arthritis.
Vivar N; Van Vollenhoven RF
Letter: NEW ENGLAND JOURNAL OF MEDICINE. 2013;369(12):1174
Case 16-2013: A Girl with Irritability, Hypersomnia, and Somatic Symptoms
van Vollenhoven RF
Review: CURRENT OPINION IN RHEUMATOLOGY. 2013;25(5):606-615
Challenges and opportunities in SLE clinical trials
van Vollenhoven RF
Editorial comment: ANNALS OF THE RHEUMATIC DISEASES. 2013;72(9):1433-1435
Novel targeted therapies: the future of rheumatoid arthritis? Mavrilumab and tabalumab as examples
Combe B; van Vollenhoven R
Editorial comment: NATURE REVIEWS. RHEUMATOLOGY. 2013;9(9):510-512
RHEUMATOID ARTHRITIS Triple therapy or etanercept after methotrexate failure in RA?
van Vollenhoven RF; Chatzidionysiou K
Review: CURRENT OPINION IN RHEUMATOLOGY. 2013;25(3):391-397
Small molecular compounds in development for rheumatoid arthritis
van Vollenhoven RF
Editorial comment: LUPUS. 2013;22(4):341
B-cell-directed therapies in systemic lupus erythematosus - where do we stand? FOREWORD
van Vollenhoven RF
Editorial comment: NATURE REVIEWS. RHEUMATOLOGY. 2013;9(2):70-72
Progress in RA genetics, pathology and therapy
van Vollenhoven RF
Review: ANNALS OF THE RHEUMATIC DISEASES. 2012;71(11):1771-1782
Joint European League Against Rheumatism and European Renal Association-European Dialysis and Transplant Association (EULAR/ERA-EDTA) recommendations for the management of adult and paediatric lupus nephritis
Bertsias GK; Tektonidou M; Amoura Z; Aringer M; Bajema I; Berden JHM; Boletis J; Cervera R; Doerner T; Doria A; Ferrario F; Floege J; Houssiau FA; Ioannidis JPA; Isenberg DA; Kallenberg CGM; Lightstone L; Marks SD; Martini A; Moroni G; Neumann I; Praga M; Schneider M; Starra A; Tesar V; Vasconcelos C; van Vollenhoven RF; Zakharova H; Haubitz M; Gordon C; Jayne D; Boumpas DT
Review: AUTOIMMUNITY REVIEWS. 2012;11(8):563-567
Rituximab - Shadow, illusion or light?
van Vollenhoven RF
Review: ANNALS OF MEDICINE. 2012;44(3):225-232
Biologicals for the treatment of systemic lupus erythematosus?
Gunnarsson I; van Vollenhoven RF
Review: JOURNAL OF INTERNAL MEDICINE. 2011;269(6):614-625
When to initiate and discontinue biologic treatments for rheumatoid arthritis?
Chatzidionysiou K; van Vollenhoven RF
Review: ANNALS OF THE RHEUMATIC DISEASES. 2011;70(6):909-920
Updated consensus statement on the use of rituximab in patients with rheumatoid arthritis
Buch MH; Smolen JS; Betteridge N; Breedveld FC; Burmester G; Doerner T; Ferraccioli G; Gottenberg J-E; Isaacs J; Kvien TK; Mariette X; Martin-Mola E; Pavelka K; Tak PP; van der Heijde D; van Vollenhoven RF; Emery P
Letter: ANNALS OF THE RHEUMATIC DISEASES. 2011;70(6):1172-1173
Rituximab-treated membranous lupus nephritis: clinical outcome and effects on electron dense deposits
Jonsdottir T; Sundelin B; Henriksson EW; van Vollenhoven RF; Gunnarsson I
Review: NATURE REVIEWS. RHEUMATOLOGY. 2011;7(4):205-215
Unresolved issues in biologic therapy for rheumatoid arthritis
van Vollenhoven RF
Editorial comment: CLINICAL RHEUMATOLOGY. 2011;30:S1-S2
Introduction
van Vollenhoven RF; Severens JL
Editorial comment: ARTHRITIS & RHEUMATOLOGY. 2011;63(3):594-596
More or Less Rituximab? Biology and Clinic, Regulators and Researchers
van Vollenhoven RF
Review: CLINICAL RHEUMATOLOGY. 2011;30:S19-S24
Observational studies: a valuable source for data on the true value of RA therapies
van Vollenhoven RF; Severens JL
Review: ANNALS OF THE RHEUMATIC DISEASES. 2010;69(12):2074-2082
EULAR recommendations for the management of systemic lupus erythematosus with neuropsychiatric manifestations: report of a task force of the EULAR standing committee for clinical affairs
Bertsias GK; Ioannidis JPA; Aringer M; Bollen E; Bombardieri S; Bruce IN; Cervera R; Dalakas M; Doria A; Hanly JG; Huizinga TWJ; Isenberg D; Kallenberg C; Piette JC; Schneider M; Scolding N; Smolen J; Stara A; Tassiulas I; Tektonidou M; Tincani A; van Buchem MA; van Vollenhoven R; Ward M; Gordon C; Boumpas DT
Review: ANNALS OF THE RHEUMATIC DISEASES. 2010;69(7):1269-1274
European League Against Rheumatism recommendations for monitoring patients with systemic lupus erythematosus in clinical practice and in observational studies
Mosca M; Tani C; Aringer M; Bombardieri S; Boumpas D; Brey R; Cervera R; Doria A; Jayne D; Khamashta MA; Kuhn A; Gordon C; Petri M; Rekvig OP; Schneider M; Sherer Y; Shoenfeld Y; Smolen JS; Talarico R; Tincani A; van Vollenhoven RF; Ward MM; Werth VP; Carmona L
Review: ANNALS OF THE RHEUMATIC DISEASES. 2010;69(6):976-986
Current evidence for the management of rheumatoid arthritis with biological disease-modifying antirheumatic drugs: a systematic literature review informing the EULAR recommendations for the management of RA
Nam JL; Winthrop KL; van Vollenhoven RF; Pavelka K; Valesini G; Hensor EMA; Worthy G; Landewe R; Smolen JS; Emery P; Buch MH
Review: ANNALS OF THE RHEUMATIC DISEASES. 2010;69(6):964-975
EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs
Smolen JS; Landewe R; Breedveld FC; Dougados M; Emery P; Gaujoux-Viala C; Gorter S; Knevel R; Nam J; Schoels M; Aletaha D; Buch M; Gossec L; Huizinga T; Bijlsma JWJW; Burmester G; Combe B; Cutolo M; Gabay C; Gomez-Reino J; Kouloumas M; Kvien TK; Martin-Mola E; McInnes I; Pavelka K; van Riel P; Scholte M; Scott DL; Sokka T; Valesini G; van Vollenhoven R; Winthrop KL; Wong J; Zink A; van der Heijde D
Review: NATURE REVIEWS. RHEUMATOLOGY. 2009;5(10):531-541
Treatment of rheumatoid arthritis: state of the art 2009
van Vollenhoven RF
Editorial comment: ANNALS OF THE RHEUMATIC DISEASES. 2009;68(8):1237-1239
How to dose infliximab in rheumatoid arthritis: new data on a serious issue
van Vollenhoven RF
Review: ANNALS OF THE RHEUMATIC DISEASES. 2009;68(4):477-483
EULAR points to consider for conducting clinical trials in systemic lupus erythematosus: literature based evidence for the selection of endpoints
Bertsias GK; Ioannidis JPA; Boletis J; Bombardieri S; Cervera R; Dostal C; Font J; Gilboe IM; Houssiau F; Huizinga T; Isenberg D; Kallenberg CGM; Khamashta M; Piette JC; Schneider M; Smolen J; Sturfelt G; Tincani A; van Vollenhoven R; Boumpas DT; Gordon C
Review: ANNALS OF THE RHEUMATIC DISEASES. 2009;68(4):470-476
EULAR points to consider for conducting clinical trials in systemic lupus erythematosus
Gordon C; Bertsias G; Ioannidis JPA; Boletis J; Bombardieri S; Cervera R; Dostal C; Font J; Gilboe I-M; Houssiau F; Huizinga TWJ; Isenberg D; Kallenberg CGM; Khamashta MA; Piette J-C; Schneider M; Smolen JS; Sturfelt G; Tincani A; Van Vollenhoven R; Boumpas DT
Editorial comment: BMC MEDICINE. 2009;7:12
Sex differences in rheumatoid arthritis: more than meets the eye ...
van Vollenhoven RF
Letter: ANNALS OF THE RHEUMATIC DISEASES. 2008;67(10):1493-1494
Prolonged B-cell depletion following rituximab therapy in systemic lupus erythematosus: a report of two cases
Lu TY-T; Jonsdottir T; van Vollenhoven RF; Isenberg DA
Review: ANNALS OF THE RHEUMATIC DISEASES. 2008;67(10):1365-1373
Methods of deriving EULAR/ACR recommendations on reporting disease activity in clinical trials of patients with rheumatoid arthritis
Karonitsch T; Aletaha D; Boers M; Bombardieri S; Combe B; Dougados M; Emery P; Felson D; Gomez-Reino J; Keystone E; Kvien TK; Martin-Mola E; Matucci-Cerinic M; Richards P; van Riel P; Siegel J; Smolen JS; Sokka T; van der Heijde D; van Vollenhoven R; Ward M; Wells G; Zink A; Landewe R
Letter: RHEUMATOLOGY. 2008;47(7):1106-1107
Comment on:: Modelling the cost effectiveness of TNF-α antagonists in the management of rheumatoid arthritis:: results from the British Society for Rheumatology Biologics Registry
van Vollenhoven RF
Published conference paper: LUPUS. 2008;17(5):447-449
The Janus of lupus - benefits and risks with B-cell therapy
van Vollenhoven RF
Review: RHEUMATOLOGY. 2008;47(4):392-398
Clinical identification and treatment of a rapidly progressing disease state in patients with rheumatoid arthritis
Emery P; McInnes IB; van Vollenhoven R; Kraan MC
Letter: ARTHRITIS & RHEUMATOLOGY. 2008;58(2):634
CD20 epitope masking by rituximab:: comment on the article by Gunnarsson et al -: Reply
Gunnarsson I; Jonsdottir T; van Vollenhoven RF
Review: ANNALS OF THE RHEUMATIC DISEASES. 2008;67(2):195-205
EULAR recommendations for the management of systemic lupus erythematosus. Report of a task force of the EULAR standing committee for international clinical studies including therapeutics
Bertsias G; Ioannidis JPA; Boletis J; Bombardieri S; Cervera R; Dostal C; Font J; Gilboe IM; Houssiau F; Huizinga T; Isenberg D; Kallenberg CGM; Khamashta M; Piette JC; Schneider M; Smolen J; Sturfelt G; Tincani A; van Vollenhoven R; Gordon C; Boumpas DT
Editorial comment: ARTHRITIS RESEARCH & THERAPY. 2008;10(2):105
Rheumatologists, take heart! We may be doing something right
van Vollenhoven RF
Editorial comment: ANNALS OF THE RHEUMATIC DISEASES. 2007;66(7):849-851
Switching between anti-tumour necrosis factors: trying to get a handle on a complex issue
van Vollenhoven RF
Editorial comment: JOURNAL OF RHEUMATOLOGY. 2006;33(12):2372-2375
Why are only 50% of courses of anti-tumor necrosis factor agents continued for only 2 years in some settings? Need for longterm observations in standard care to complement clinical trials
Pincus T; Yazici Y; van Vollenhoven R
Letter: NEPHROLOGY DIALYSIS TRANSPLANTATION. 2006;21(6):1742-1743
Rituximab-induced long-term remission of membranous lupus nephritis
Jacobson SH; van Vollenhoven R; Gunnarsson I
Review: ANNALS OF THE RHEUMATIC DISEASES. 2006;65(6):707-712
Swedish registers to examine drug safety and clinical issues in RA
Askling J; Fored CM; Geborek P; Jacobsson LTH; van Vollenhoven R; Feltelius N; Lindblad S; Klareskog L
Letter: ARTHRITIS & RHEUMATOLOGY. 2005;52(12):4050-4051
In lupus nephritis, the benefit of rituximab monotherapy, as opposed to rituximab plus cyclophosphamide combination therapy, remains uncertain: comment on the article by Sfikakis et al
van Vollenhoven R; Gunnarsson I
Letter: ARTHRITIS & RHEUMATOLOGY. 2005;53(4):626
Dehydroepiandrosterone versus placebo for Sjogren's syndrome: comment on the article by Pillemer et al
van Vollenhoven R
Editorial comment: ARTHRITIS & RHEUMATOLOGY. 2005;52(4):991-994
The treatment of rheumatoid arthritis: Getting better all the time?
van Vollenhoven RF; Klareskog L
Published conference paper: ARTHRITIS & RHEUMATOLOGY. 2004;50(9):2858-2868
Effects of prasterone on disease activity and symptoms in women with active systemic lupus erythematosus - Results of a multicenter randomized, double-blind, placebo-controlled trial
Petri MA; Mease PJ; Merrill JT; Lahita RG; Iannini MJ; Yocum DE; Ginzler EM; Katz RS; Gluck OS; Genovese MC; Van Vollenhoven R; Kalunian KC; Manzi S; Greenwald MW; Buyon JP; Olsen NJ; Schiff MH; Kavanaugh AF; Caldwell JR; Ramsey-Goldman R; St Clair EW; Goldman AL; Egan RM; Polisson RP; Moder KG; Rothfield NF; Spencer RT; Hobbs K; Fessler BJ; Calabrese LH; Moreland LW; Cohen SB; Quarles BJ; Strand V; Gurwith M; Schwartz KE
Letter: ANNALS OF THE RHEUMATIC DISEASES. 2004;63(5):608
Do etanercept-naive patients with rheumatoid arthritis respond better to infliximab than patients for whom etanercept has failed? Reply
van Vollenhoven RF
Published conference paper: ARTHRITIS & RHEUMATOLOGY. 2002;46(7):1820-1829
Effects of prasterone on corticosteroid requirements of women with systemic lupus erythematosus: a double-blind, randomized, placebo-controlled trial.
Petri MA; Lahita RG; Van Vollenhoven RF; Merrill JT; Schiff M; Ginzler EM; Strand V; Kunz A; Gorelick KJ; Schwartz KE; GL601 Study Group
Review: EXPERT OPINION ON PHARMACOTHERAPY. 2002;3(1):23-31
Dehydroepiandrosterone for the treatment of systemic lupus erythematosus.
van Vollenhoven RF
Review: LAKARTIDNINGEN. 2001;98(8):828-831
[Blockade of TNFalpha--new therapeutic principle in severe rheumatoid arthritis].
Larsson P; Bratt J; Harju A; van Vollenhoven R; Klareskog L
Letter: RHEUMATOLOGY. 2000;39(8):929-930
Dehydroepiandrosterone in the treatment of systemic lupus erythematosus
van Vollenhoven RF
Letter: ARTHRITIS & RHEUMATOLOGY. 1998;41(10):1897
Role of sex steroids in the Th1/Th2 cytokine balance: comment on the article by Miossec and van den Berg.
van Vollenhoven RF
Editorial comment: POSTGRADUATE MEDICINE. 1998;103(2):67
Rheumatology in primary care - A five-article symposium
van Vollenhoven RF
Review: ANNALES DE MEDECINE INTERNE. 1996;147(4):265-273
Systemic lupus erythematosus and pregnancy.
Druzin ML; Van Vollenhoven RF
Editorial comment: ANNALES DE MEDECINE INTERNE. 1996;147(4):239-240
Hormones and systemic lupus erythematosus
VanVollenhoven RF
Letter: NEW ENGLAND JOURNAL OF MEDICINE. 1995;333(21):1424
BREAST IMPLANTS AND CONNECTIVE-TISSUE DISEASES
VANVOLLENHOVEN R
Visa fler

Artiklar

Alla övriga publikationer

Anställningar

Examina och utbildning

Nyheter från KI

Kalenderhändelser från KI